CN116194453A - 蛋白质酪氨酸磷酸酶降解剂及其使用方法 - Google Patents
蛋白质酪氨酸磷酸酶降解剂及其使用方法 Download PDFInfo
- Publication number
- CN116194453A CN116194453A CN202080097241.6A CN202080097241A CN116194453A CN 116194453 A CN116194453 A CN 116194453A CN 202080097241 A CN202080097241 A CN 202080097241A CN 116194453 A CN116194453 A CN 116194453A
- Authority
- CN
- China
- Prior art keywords
- compound
- alkyl
- hydrogen
- membered
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 79
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 title abstract description 24
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 title abstract description 24
- 230000000593 degrading effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 723
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 claims abstract description 24
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 13
- 101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 claims abstract description 10
- 201000011510 cancer Diseases 0.000 claims abstract description 10
- 102100033141 Tyrosine-protein phosphatase non-receptor type 2 Human genes 0.000 claims abstract description 6
- 208000030159 metabolic disease Diseases 0.000 claims abstract description 6
- 101001135572 Homo sapiens Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 claims abstract 4
- 239000001257 hydrogen Substances 0.000 claims description 189
- 229910052739 hydrogen Inorganic materials 0.000 claims description 189
- -1 hydroxy, methoxy Chemical group 0.000 claims description 181
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 106
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 100
- 125000001153 fluoro group Chemical group F* 0.000 claims description 92
- 125000002947 alkylene group Chemical group 0.000 claims description 85
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 83
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 77
- 125000001424 substituent group Chemical group 0.000 claims description 75
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 65
- 150000003839 salts Chemical class 0.000 claims description 63
- 229910052736 halogen Chemical group 0.000 claims description 58
- 150000002367 halogens Chemical group 0.000 claims description 55
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 54
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 50
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 46
- 125000004432 carbon atom Chemical group C* 0.000 claims description 44
- 125000000732 arylene group Chemical group 0.000 claims description 39
- 125000006587 (C5-C10) heteroarylene group Chemical group 0.000 claims description 37
- 125000000623 heterocyclic group Chemical group 0.000 claims description 36
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 33
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 31
- 125000005549 heteroarylene group Chemical group 0.000 claims description 30
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 29
- 125000000217 alkyl group Chemical group 0.000 claims description 25
- 125000004450 alkenylene group Chemical group 0.000 claims description 23
- 108090000623 proteins and genes Proteins 0.000 claims description 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 21
- 125000006677 (C1-C3) haloalkoxy group Chemical group 0.000 claims description 20
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 20
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 20
- 239000005977 Ethylene Chemical group 0.000 claims description 20
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 20
- 125000006769 halocycloalkoxy group Chemical group 0.000 claims description 20
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 20
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 125000002619 bicyclic group Chemical group 0.000 claims description 19
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
- 125000004043 oxo group Chemical group O=* 0.000 claims description 17
- 125000004419 alkynylene group Chemical group 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 125000001188 haloalkyl group Chemical group 0.000 claims description 12
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 125000004076 pyridyl group Chemical group 0.000 claims description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims description 7
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 7
- 238000001727 in vivo Methods 0.000 claims description 7
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 7
- 125000004193 piperazinyl group Chemical group 0.000 claims description 7
- 125000003386 piperidinyl group Chemical group 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- 125000005494 pyridonyl group Chemical group 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 5
- 229910052720 vanadium Inorganic materials 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 208000016097 disease of metabolism Diseases 0.000 claims description 4
- 125000005551 pyridylene group Chemical group 0.000 claims description 4
- 230000000638 stimulation Effects 0.000 claims description 4
- 125000005559 triazolylene group Chemical group 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- 206010027476 Metastases Diseases 0.000 claims description 2
- 150000001721 carbon Chemical group 0.000 claims description 2
- 125000004976 cyclobutylene group Chemical group 0.000 claims description 2
- 125000004956 cyclohexylene group Chemical group 0.000 claims description 2
- 125000004979 cyclopentylene group Chemical group 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 2
- 230000004584 weight gain Effects 0.000 claims description 2
- 235000019786 weight gain Nutrition 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims 12
- 210000004962 mammalian cell Anatomy 0.000 claims 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 125000004957 naphthylene group Chemical group 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 143
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 16
- 102000005962 receptors Human genes 0.000 abstract description 15
- 108020003175 receptors Proteins 0.000 abstract description 15
- 239000003112 inhibitor Substances 0.000 abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 350
- 239000000243 solution Substances 0.000 description 213
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 176
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 173
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 169
- 239000011541 reaction mixture Substances 0.000 description 167
- 239000007787 solid Substances 0.000 description 158
- 230000002829 reductive effect Effects 0.000 description 143
- 235000019439 ethyl acetate Nutrition 0.000 description 138
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 135
- 239000012071 phase Substances 0.000 description 129
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 113
- 229910001868 water Inorganic materials 0.000 description 113
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 102
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 88
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 84
- 238000006243 chemical reaction Methods 0.000 description 70
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 64
- 238000005481 NMR spectroscopy Methods 0.000 description 59
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 59
- 239000012044 organic layer Substances 0.000 description 58
- 239000012267 brine Substances 0.000 description 52
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 52
- 230000002441 reversible effect Effects 0.000 description 45
- 238000000746 purification Methods 0.000 description 44
- 238000010898 silica gel chromatography Methods 0.000 description 43
- 238000002953 preparative HPLC Methods 0.000 description 41
- 239000002904 solvent Substances 0.000 description 41
- 125000005842 heteroatom Chemical group 0.000 description 39
- OFWSONIJPUAWAP-UHFFFAOYSA-N 1-[2-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]amino]acetyl]-N-[2-[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxyethyl]piperidine-4-carboxamide Chemical compound O=S1(N(CC(N1)=O)C1=C(C=C2C=CC(=CC2=C1F)OCCNC(=O)C1CCN(CC1)C(CNC1=C2CN(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O)O)=O OFWSONIJPUAWAP-UHFFFAOYSA-N 0.000 description 38
- 239000007864 aqueous solution Substances 0.000 description 38
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 37
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 36
- 125000003118 aryl group Chemical group 0.000 description 35
- 239000011734 sodium Substances 0.000 description 35
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 33
- 239000003208 petroleum Substances 0.000 description 32
- NSPFRKJIMWGLTA-UHFFFAOYSA-N N-[2-[4-[1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxobenzimidazol-5-yl]piperidin-1-yl]ethyl]-5-fluoro-7-phenylmethoxy-6-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalene-2-carboxamide Chemical compound C(C1=CC=CC=C1)OC1=C(C(=C2C=CC(=CC2=C1)C(=O)NCCN1CCC(CC1)C1=CC2=C(N(C(N2C)=O)C2C(NC(CC2)=O)=O)C=C1)F)N1S(NC(C1)=O)(=O)=O NSPFRKJIMWGLTA-UHFFFAOYSA-N 0.000 description 31
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 27
- 125000001072 heteroaryl group Chemical group 0.000 description 27
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 26
- DMUVIDOMCXBUKX-UHFFFAOYSA-N 3-[5-[1-[[5-[5-fluoro-7-phenylmethoxy-6-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]-1,3,4-oxadiazol-2-yl]methyl]piperidin-4-yl]-3-methyl-2-oxobenzimidazol-1-yl]piperidine-2,6-dione Chemical compound C(C1=CC=CC=C1)OC1=C(C(=C2C=CC(=CC2=C1)C1=NN=C(O1)CN1CCC(CC1)C1=CC2=C(N(C(N2C)=O)C2C(NC(CC2)=O)=O)C=C1)F)N1S(NC(C1)=O)(=O)=O DMUVIDOMCXBUKX-UHFFFAOYSA-N 0.000 description 24
- RMXBRBLNDHLQJF-UHFFFAOYSA-N 2-[4-[3-(2,6-dioxopiperidin-3-yl)-2-oxo-1,3-benzoxazol-6-yl]piperidin-1-yl]-N-[2-[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxyethyl]acetamide Chemical compound O=C1NC(CCC1N1C(OC2=C1C=CC(=C2)C1CCN(CC1)CC(=O)NCCOC1=CC2=C(C(=C(C=C2C=C1)O)N1S(NC(C1)=O)(=O)=O)F)=O)=O RMXBRBLNDHLQJF-UHFFFAOYSA-N 0.000 description 23
- 239000000706 filtrate Substances 0.000 description 22
- 229910052757 nitrogen Inorganic materials 0.000 description 22
- 239000000460 chlorine Substances 0.000 description 21
- 229910052938 sodium sulfate Inorganic materials 0.000 description 21
- 235000011152 sodium sulphate Nutrition 0.000 description 21
- 239000003039 volatile agent Substances 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 19
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 17
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 17
- AXHBJJWSRDHTGA-UHFFFAOYSA-N 2-[4-[1-(2,6-dioxopiperidin-3-yl)-2-oxobenzo[cd]indol-6-yl]piperidin-1-yl]-N-[2-[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxyethyl]acetamide Chemical compound O=S1(N(CC(N1)=O)C1=C(C=C2C=CC(=CC2=C1F)OCCNC(CN1CCC(CC1)C=1C=2C3=C(C(N(C3=CC=1)C1C(NC(CC1)=O)=O)=O)C=CC=2)=O)O)=O AXHBJJWSRDHTGA-UHFFFAOYSA-N 0.000 description 16
- NZPMKGNCJRNXNW-UHFFFAOYSA-N 2-[4-[3-(2,6-dioxopiperidin-3-yl)-1-methylindazol-6-yl]piperidin-1-yl]-N-[2-[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxyethyl]acetamide Chemical compound O=C1NC(CCC1C1=NN(C2=CC(=CC=C12)C1CCN(CC1)CC(=O)NCCOC1=CC2=C(C(=C(C=C2C=C1)O)N1S(NC(C1)=O)(=O)=O)F)C)=O NZPMKGNCJRNXNW-UHFFFAOYSA-N 0.000 description 16
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 16
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 16
- 201000010099 disease Diseases 0.000 description 15
- 239000012074 organic phase Substances 0.000 description 15
- USLKIQHJIVBSBF-UHFFFAOYSA-N 2-[4-[1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxobenzimidazol-4-yl]oxypiperidin-1-yl]-N-[2-[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxyethyl]acetamide Chemical compound O=C1NC(CCC1N1C(N(C2=C1C=CC=C2OC1CCN(CC1)CC(=O)NCCOC1=CC2=C(C(=C(C=C2C=C1)O)N1S(NC(C1)=O)(=O)=O)F)C)=O)=O USLKIQHJIVBSBF-UHFFFAOYSA-N 0.000 description 14
- GMZCXBUTFIORFL-UHFFFAOYSA-N 2-[4-[4-[(2,6-dioxopiperidin-3-yl)amino]-2-fluorophenyl]piperidin-1-yl]-N-[2-[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxyethyl]acetamide Chemical compound O=C1NC(CCC1NC1=CC(=C(C=C1)C1CCN(CC1)CC(=O)NCCOC1=CC2=C(C(=C(C=C2C=C1)O)N1S(NC(C1)=O)(=O)=O)F)F)=O GMZCXBUTFIORFL-UHFFFAOYSA-N 0.000 description 14
- 108010015847 Non-Receptor Type 1 Protein Tyrosine Phosphatase Proteins 0.000 description 14
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 14
- 125000003342 alkenyl group Chemical group 0.000 description 14
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 14
- 238000003756 stirring Methods 0.000 description 14
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 13
- 239000012298 atmosphere Substances 0.000 description 13
- 239000012299 nitrogen atmosphere Substances 0.000 description 12
- AHQLLJWRLPUEQK-UHFFFAOYSA-N O=S1(N(CC(N1)=O)C1=C(C=C2C=CC(=CC2=C1F)C=CC(=O)NC1CCN(CC1)C(COC1=C2CN(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O)O)=O Chemical compound O=S1(N(CC(N1)=O)C1=C(C=C2C=CC(=CC2=C1F)C=CC(=O)NC1CCN(CC1)C(COC1=C2CN(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O)O)=O AHQLLJWRLPUEQK-UHFFFAOYSA-N 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 229910052717 sulfur Chemical group 0.000 description 11
- UQIWJQCOXXJSMQ-UHFFFAOYSA-N 5-(6-amino-1-fluoro-3-hydroxynaphthalen-2-yl)-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound NC=1C=C2C=C(C(=C(C2=CC=1)F)N1CC(NS1(=O)=O)=O)O UQIWJQCOXXJSMQ-UHFFFAOYSA-N 0.000 description 10
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 10
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 10
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 10
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 10
- 229910052760 oxygen Inorganic materials 0.000 description 10
- 239000001301 oxygen Chemical group 0.000 description 10
- 239000011593 sulfur Chemical group 0.000 description 10
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 9
- HRHDKWPJLUEURA-UHFFFAOYSA-N 5-(6-amino-1-fluoro-3-phenylmethoxynaphthalen-2-yl)-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound NC=1C=C2C=C(C(=C(C2=CC=1)F)N1CC(NS1(=O)=O)=O)OCC1=CC=CC=C1 HRHDKWPJLUEURA-UHFFFAOYSA-N 0.000 description 9
- 150000008064 anhydrides Chemical class 0.000 description 9
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 9
- 229910000024 caesium carbonate Inorganic materials 0.000 description 9
- 125000004122 cyclic group Chemical group 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 239000010410 layer Substances 0.000 description 9
- BEZDDPMMPIDMGJ-UHFFFAOYSA-N pentamethylbenzene Chemical compound CC1=CC(C)=C(C)C(C)=C1C BEZDDPMMPIDMGJ-UHFFFAOYSA-N 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 9
- 230000019491 signal transduction Effects 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 8
- NRYYOIDGBATHHX-UHFFFAOYSA-N 3-[4-[[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]methyl]pyrazol-1-yl]-N-[5-fluoro-7-hydroxy-6-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]propanamide Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NCC=1C=NN(C=1)CCC(=O)NC1=CC2=CC(=C(C(=C2C=C1)F)N1S(NC(C1)=O)(=O)=O)O)=O)=O NRYYOIDGBATHHX-UHFFFAOYSA-N 0.000 description 8
- NWQRUFMPOLTMEL-UHFFFAOYSA-N 3-[4-[[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]amino]methyl]pyrazol-1-yl]-N-[5-fluoro-7-hydroxy-6-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]propanamide Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1)NCC=1C=NN(C=1)CCC(=O)NC1=CC2=CC(=C(C(=C2C=C1)F)N1S(NC(C1)=O)(=O)=O)O)=O)=O NWQRUFMPOLTMEL-UHFFFAOYSA-N 0.000 description 8
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- 239000007832 Na2SO4 Substances 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 8
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 8
- XJSVTABFNIZANR-UHFFFAOYSA-N 3-[4-[[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]amino]methyl]triazol-1-yl]-N-[5-fluoro-7-hydroxy-6-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]propanamide Chemical compound O=S1(N(CC(N1)=O)C=1C(=C2C=CC(=CC2=CC=1O)NC(CCN1N=NC(=C1)CNC=1C=C2C(N(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)=O)=O)F)=O XJSVTABFNIZANR-UHFFFAOYSA-N 0.000 description 7
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 7
- PVEIIZOCROOUKI-UHFFFAOYSA-N NCCOC1=CC=C2C=C(C(=C(C2=C1)F)N1CC(NS1(=O)=O)=O)O Chemical compound NCCOC1=CC=C2C=C(C(=C(C2=C1)F)N1CC(NS1(=O)=O)=O)O PVEIIZOCROOUKI-UHFFFAOYSA-N 0.000 description 7
- 229910052796 boron Inorganic materials 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 125000001624 naphthyl group Chemical group 0.000 description 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- 230000006663 ubiquitin-proteasome pathway Effects 0.000 description 7
- BWQZJGJCYZYXMU-UHFFFAOYSA-N 2-[4-[3-(2,6-dioxopiperidin-3-yl)-2-oxo-1,3-benzoxazol-6-yl]piperidin-1-yl]acetic acid Chemical compound O=C1NC(CCC1N1C(OC2=C1C=CC(=C2)C1CCN(CC1)CC(=O)O)=O)=O BWQZJGJCYZYXMU-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- GMROAXLUUTZXAU-UHFFFAOYSA-N OC(=O)CCN1C=C(C=O)C=N1 Chemical compound OC(=O)CCN1C=C(C=O)C=N1 GMROAXLUUTZXAU-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 6
- 150000003840 hydrochlorides Chemical class 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 6
- VVDCRJGWILREQH-UHFFFAOYSA-N tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC(B2OC(C)(C)C(C)(C)O2)=C1 VVDCRJGWILREQH-UHFFFAOYSA-N 0.000 description 6
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 5
- RSVYFTJXQDAKPI-UHFFFAOYSA-N 1-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]acetyl]-N-[2-[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxyethyl]piperidine-4-carboxamide Chemical compound O=S1(N(CC(N1)=O)C1=C(C=C2C=CC(=CC2=C1F)OCCNC(=O)C1CCN(CC1)C(CNC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O)=O)O)=O RSVYFTJXQDAKPI-UHFFFAOYSA-N 0.000 description 5
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 5
- WQFWDKGZOWTBSB-UHFFFAOYSA-N 2-[4-[1-(2,6-dioxopiperidin-3-yl)-2-oxobenzo[cd]indol-6-yl]piperidin-1-yl]-N-[5-fluoro-7-hydroxy-6-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]acetamide Chemical compound O=C1NC(CCC1N1C(C2=C3C(C(=CC=C13)C1CCN(CC1)CC(=O)NC1=CC3=CC(=C(C(=C3C=C1)F)N1S(NC(C1)=O)(=O)=O)O)=CC=C2)=O)=O WQFWDKGZOWTBSB-UHFFFAOYSA-N 0.000 description 5
- RDIPUHWHXRMGKZ-UHFFFAOYSA-N 2-[4-[1-(2,6-dioxopiperidin-3-yl)-2-oxobenzo[cd]indol-6-yl]piperidin-1-yl]acetic acid Chemical compound O=C1NC(CCC1N1C(C2=C3C(C(=CC=C13)C1CCN(CC1)CC(=O)O)=CC=C2)=O)=O RDIPUHWHXRMGKZ-UHFFFAOYSA-N 0.000 description 5
- CYEVACCBOMWWSU-UHFFFAOYSA-N 2-[4-[1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxobenzimidazol-4-yl]piperidin-1-yl]-N-[5-fluoro-7-hydroxy-6-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]acetamide Chemical compound O=C1NC(CCC1N1C(N(C2=C1C=CC=C2C1CCN(CC1)CC(=O)NC1=CC2=CC(=C(C(=C2C=C1)F)N1S(NC(C1)=O)(=O)=O)O)C)=O)=O CYEVACCBOMWWSU-UHFFFAOYSA-N 0.000 description 5
- JWQAWFCWTSDXJB-UHFFFAOYSA-N 2-[4-[1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxobenzimidazol-5-yl]piperidin-1-yl]-N-[5-fluoro-7-hydroxy-6-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]acetamide Chemical compound O=S1(N(CC(N1)=O)C=1C(=C2C=CC(=CC2=CC=1O)NC(CN1CCC(CC1)C1=CC2=C(N(C(N2C)=O)C2C(NC(CC2)=O)=O)C=C1)=O)F)=O JWQAWFCWTSDXJB-UHFFFAOYSA-N 0.000 description 5
- FODVSKCWQROUOW-UHFFFAOYSA-N 2-[4-[1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxobenzimidazol-5-yl]piperidin-1-yl]acetic acid Chemical compound O=C1NC(CCC1N1C(N(C2=C1C=CC(=C2)C1CCN(CC1)CC(=O)O)C)=O)=O FODVSKCWQROUOW-UHFFFAOYSA-N 0.000 description 5
- KZHRHKNIVPZPGZ-UHFFFAOYSA-N 2-[4-[3-(2,6-dioxopiperidin-3-yl)-2-oxo-1,3-benzoxazol-6-yl]piperidin-1-yl]-N-[5-fluoro-7-hydroxy-6-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]acetamide Chemical compound O=C1NC(CCC1N1C(OC2=C1C=CC(=C2)C1CCN(CC1)CC(=O)NC1=CC2=CC(=C(C(=C2C=C1)F)N1S(NC(C1)=O)(=O)=O)O)=O)=O KZHRHKNIVPZPGZ-UHFFFAOYSA-N 0.000 description 5
- WLUMAGCINIWKIB-UHFFFAOYSA-N 3-[4-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]oxymethyl]pyrazol-1-yl]-N-[5-fluoro-7-hydroxy-6-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]propanamide Chemical compound O=S1(N(CC(N1)=O)C=1C(=C2C=CC(=CC2=CC=1O)NC(CCN1N=CC(=C1)COC1=C2CN(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O)F)=O WLUMAGCINIWKIB-UHFFFAOYSA-N 0.000 description 5
- BXZLHEWJJHNEPZ-UHFFFAOYSA-N 3-[4-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]oxymethyl]triazol-1-yl]-N-[5-fluoro-7-hydroxy-6-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]propanamide Chemical compound O=S1(N(CC(N1)=O)C=1C(=C2C=CC(=CC2=CC=1O)NC(CCN1N=NC(=C1)COC1=C2CN(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O)F)=O BXZLHEWJJHNEPZ-UHFFFAOYSA-N 0.000 description 5
- BMVWDPQAXRFXMQ-UHFFFAOYSA-N 3-[4-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]oxymethyl]triazol-1-yl]-N-[5-fluoro-7-hydroxy-6-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]propanamide Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1)OCC=1N=NN(C=1)CCC(=O)NC1=CC2=CC(=C(C(=C2C=C1)F)N1S(NC(C1)=O)(=O)=O)O)=O)=O BMVWDPQAXRFXMQ-UHFFFAOYSA-N 0.000 description 5
- HTWBXMIIAFDDFO-UHFFFAOYSA-N 3-[4-[[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]methyl]triazol-1-yl]-N-[5-fluoro-7-hydroxy-6-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]azetidine-1-carboxamide Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NCC=1N=NN(C=1)C1CN(C1)C(=O)NC1=CC2=CC(=C(C(=C2C=C1)F)N1S(NC(C1)=O)(=O)=O)O)=O)=O HTWBXMIIAFDDFO-UHFFFAOYSA-N 0.000 description 5
- LJAZAKQITGEZRQ-UHFFFAOYSA-N 3-[4-[[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]amino]methyl]pyrazol-1-yl]-N-[5-fluoro-7-hydroxy-6-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]propanamide Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1)NCC=1C=NN(C=1)CCC(=O)NC1=CC2=CC(=C(C(=C2C=C1)F)N1S(NC(C1)=O)(=O)=O)O)=O)=O LJAZAKQITGEZRQ-UHFFFAOYSA-N 0.000 description 5
- HMBUZAAKYFYQKL-UHFFFAOYSA-N 3-[4-[[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]amino]methyl]triazol-1-yl]-N-[5-fluoro-7-hydroxy-6-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]propanamide Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1)NCC=1N=NN(C=1)CCC(=O)NC1=CC2=CC(=C(C(=C2C=C1)F)N1S(NC(C1)=O)(=O)=O)O)=O)=O HMBUZAAKYFYQKL-UHFFFAOYSA-N 0.000 description 5
- YIPVUXAMZQBALD-UHFFFAOYSA-N 3-azidopropanoic acid Chemical compound OC(=O)CCN=[N+]=[N-] YIPVUXAMZQBALD-UHFFFAOYSA-N 0.000 description 5
- RYSICGXZRVMXDP-UHFFFAOYSA-N 3-bromopiperidine-2,6-dione Chemical compound BrC1CCC(=O)NC1=O RYSICGXZRVMXDP-UHFFFAOYSA-N 0.000 description 5
- ORQJQMXWAHFKEZ-UHFFFAOYSA-N 5-(7-bromo-1-fluoro-3-phenylmethoxynaphthalen-2-yl)-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound C=1C=CC=CC=1COC1=CC2=CC=C(Br)C=C2C(F)=C1N1CC(=O)NS1(=O)=O ORQJQMXWAHFKEZ-UHFFFAOYSA-N 0.000 description 5
- QHFNCJUECLMWNY-UHFFFAOYSA-N 5-[7-(2-aminoethoxy)-1-fluoro-3-phenylmethoxynaphthalen-2-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound NCCOC1=CC=C2C=C(C(=C(C2=C1)F)N1CC(NS1(=O)=O)=O)OCC1=CC=CC=C1 QHFNCJUECLMWNY-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 239000005909 Kieselgur Substances 0.000 description 5
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 description 5
- 125000004430 oxygen atom Chemical group O* 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000002285 radioactive effect Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- SMBUDCVPSMAQLS-UHFFFAOYSA-N tert-butyl 4-(1h-indazol-6-yl)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC(C=2C=C3NN=CC3=CC=2)=C1 SMBUDCVPSMAQLS-UHFFFAOYSA-N 0.000 description 5
- 229960003433 thalidomide Drugs 0.000 description 5
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 4
- NGQLOGOJTSWWFU-UHFFFAOYSA-N 2-[3-[[1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxobenzimidazol-5-yl]amino]azetidin-1-yl]-N-[5-fluoro-7-hydroxy-6-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]acetamide Chemical compound O=C1NC(CCC1N1C(N(C2=C1C=CC(=C2)NC1CN(C1)CC(=O)NC1=CC2=CC(=C(C(=C2C=C1)F)N1S(NC(C1)=O)(=O)=O)O)C)=O)=O NGQLOGOJTSWWFU-UHFFFAOYSA-N 0.000 description 4
- QSQSZRIQEQEQNJ-UHFFFAOYSA-N 2-[4-[1-(2,6-dioxopiperidin-3-yl)-2-oxo-3-propan-2-ylbenzimidazol-5-yl]piperidin-1-yl]-N-[5-fluoro-7-hydroxy-6-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]acetamide Chemical compound O=C1NC(CCC1N1C(N(C2=C1C=CC(=C2)C1CCN(CC1)CC(=O)NC1=CC2=CC(=C(C(=C2C=C1)F)N1S(NC(C1)=O)(=O)=O)O)C(C)C)=O)=O QSQSZRIQEQEQNJ-UHFFFAOYSA-N 0.000 description 4
- NBZNLFIMOBYJBB-UHFFFAOYSA-N 2-[4-[1-(2,6-dioxopiperidin-3-yl)-2-oxo-3-propan-2-ylbenzimidazol-5-yl]piperidin-1-yl]acetic acid Chemical compound O=C1NC(CCC1N1C(N(C2=C1C=CC(=C2)C1CCN(CC1)CC(=O)O)C(C)C)=O)=O NBZNLFIMOBYJBB-UHFFFAOYSA-N 0.000 description 4
- QBLFILKMESTMQC-UHFFFAOYSA-N 2-[4-[4-[(2,6-dioxopiperidin-3-yl)amino]-2-fluorophenyl]piperidin-1-yl]acetic acid Chemical compound O=C1NC(CCC1NC1=CC(=C(C=C1)C1CCN(CC1)CC(=O)O)F)=O QBLFILKMESTMQC-UHFFFAOYSA-N 0.000 description 4
- ODMQHYXPTUCRDC-UHFFFAOYSA-N 2-bromo-n-methyl-6-nitroaniline Chemical compound CNC1=C(Br)C=CC=C1[N+]([O-])=O ODMQHYXPTUCRDC-UHFFFAOYSA-N 0.000 description 4
- DGAFGFOJSQHBGS-UHFFFAOYSA-N 3-(3-methyl-2-oxo-4-piperidin-4-yloxybenzimidazol-1-yl)piperidine-2,6-dione Chemical compound CN1C(N(C2=C1C(=CC=C2)OC1CCNCC1)C1C(NC(CC1)=O)=O)=O DGAFGFOJSQHBGS-UHFFFAOYSA-N 0.000 description 4
- WLUIQUZGNPAKRL-UHFFFAOYSA-N 3-(6-amino-3-oxo-1h-isoindol-2-yl)piperidine-2,6-dione Chemical compound C1C2=CC(N)=CC=C2C(=O)N1C1CCC(=O)NC1=O WLUIQUZGNPAKRL-UHFFFAOYSA-N 0.000 description 4
- HGPRKOYQOBYISD-UHFFFAOYSA-N 3-(7-hydroxy-3-oxo-1h-isoindol-2-yl)piperidine-2,6-dione Chemical compound C1C=2C(O)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O HGPRKOYQOBYISD-UHFFFAOYSA-N 0.000 description 4
- UTXIWJMGVWGKLN-UHFFFAOYSA-N 3-[4-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]propan-2-yl]triazol-1-yl]propanoic acid Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NC(C)(C)C=1N=NN(C=1)CCC(=O)O)=O)=O UTXIWJMGVWGKLN-UHFFFAOYSA-N 0.000 description 4
- DBEGYWMMFXIXJN-UHFFFAOYSA-N 3-[4-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]oxymethyl]pyrazol-1-yl]propanoic acid Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1)OCC=1C=NN(C=1)CCC(=O)O)=O)=O DBEGYWMMFXIXJN-UHFFFAOYSA-N 0.000 description 4
- JKABMDNHPNKPIB-UHFFFAOYSA-N 3-[4-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]oxymethyl]triazol-1-yl]propanoic acid Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1)OCC=1N=NN(C=1)CCC(=O)O)=O)=O JKABMDNHPNKPIB-UHFFFAOYSA-N 0.000 description 4
- DJHNCUQGEJCWSU-UHFFFAOYSA-N 3-[4-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]oxymethyl]triazol-1-yl]propanoic acid Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1)OCC=1N=NN(C=1)CCC(=O)O)=O)=O DJHNCUQGEJCWSU-UHFFFAOYSA-N 0.000 description 4
- ODOPEASCALEEFT-UHFFFAOYSA-N 3-[4-[[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]amino]methyl]triazol-1-yl]propanoic acid Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)NCC=1N=NN(C=1)CCC(=O)O)=O)=O ODOPEASCALEEFT-UHFFFAOYSA-N 0.000 description 4
- MJNOZMIBXPPVQI-UHFFFAOYSA-N 3-[4-[[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]amino]methyl]pyrazol-1-yl]propanoic acid Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1)NCC=1C=NN(C=1)CCC(=O)O)=O)=O MJNOZMIBXPPVQI-UHFFFAOYSA-N 0.000 description 4
- YPXNCKMFGYNKLX-UHFFFAOYSA-N 3-[5-(azetidin-3-ylamino)-3-methyl-2-oxobenzimidazol-1-yl]piperidine-2,6-dione Chemical compound N1CC(C1)NC1=CC2=C(N(C(N2C)=O)C2C(NC(CC2)=O)=O)C=C1 YPXNCKMFGYNKLX-UHFFFAOYSA-N 0.000 description 4
- TXTSJSNNSHPJEG-UHFFFAOYSA-N 4-[[1-(azetidin-3-yl)triazol-4-yl]methylamino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound N1CC(C1)N1N=NC(=C1)CNC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O TXTSJSNNSHPJEG-UHFFFAOYSA-N 0.000 description 4
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 4
- KKINJYIBQOYIST-UHFFFAOYSA-N 5-(6-bromo-1-fluoro-3-phenylmethoxynaphthalen-2-yl)-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound C(C1=CC=CC=C1)OC=1C(=C(C2=CC=C(C=C2C=1)Br)F)N1CC(NS1(=O)=O)=O KKINJYIBQOYIST-UHFFFAOYSA-N 0.000 description 4
- XYWVXAHNBHHCBV-UHFFFAOYSA-N 5-[7-(2-aminoethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one hydrochloride Chemical compound C1C(=O)NS(=O)(=O)N1C2=C(C=C3C=CC(=CC3=C2F)OCCN)O.Cl XYWVXAHNBHHCBV-UHFFFAOYSA-N 0.000 description 4
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 4
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- 229910015844 BCl3 Inorganic materials 0.000 description 4
- FJMWWLNEKGHSNO-UHFFFAOYSA-N CN1C(N(C2=C1C=C(C=C2)C1CCNCC1)C1C(NC(CC1)=O)=O)=O Chemical compound CN1C(N(C2=C1C=C(C=C2)C1CCNCC1)C1C(NC(CC1)=O)=O)=O FJMWWLNEKGHSNO-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 208000033962 Fontaine progeroid syndrome Diseases 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- 102100032783 Protein cereblon Human genes 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 125000005493 quinolyl group Chemical group 0.000 description 4
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- MWXHGVYCDFDVTK-UHFFFAOYSA-N tert-butyl 4-[3-(2,6-dioxopiperidin-3-yl)-1-methylindazol-6-yl]piperidine-1-carboxylate Chemical compound O=C1NC(CCC1C1=NN(C2=CC(=CC=C12)C1CCN(CC1)C(=O)OC(C)(C)C)C)=O MWXHGVYCDFDVTK-UHFFFAOYSA-N 0.000 description 4
- LAJZESYRPKBCBA-UHFFFAOYSA-N tert-butyl N-[2-[8-fluoro-6-phenylmethoxy-7-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxyethyl]carbamate Chemical compound C(C1=CC=CC=C1)OC=1C=C2C=CC(=CC2=C(C=1N1S(NC(C1)=O)(=O)=O)F)OCCNC(OC(C)(C)C)=O LAJZESYRPKBCBA-UHFFFAOYSA-N 0.000 description 4
- POIJCAVVHCEANL-UHFFFAOYSA-N tert-butyl N-[5-fluoro-7-phenylmethoxy-6-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]carbamate Chemical compound C(C1=CC=CC=C1)OC1=C(C(=C2C=CC(=CC2=C1)NC(OC(C)(C)C)=O)F)N1S(NC(C1)=O)(=O)=O POIJCAVVHCEANL-UHFFFAOYSA-N 0.000 description 4
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 3
- QBOWEDKHENDSKU-VQHVLOKHSA-N (E)-3-[8-fluoro-6-phenylmethoxy-7-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]prop-2-enoic acid Chemical compound C(C1=CC=CC=C1)OC=1C=C2C=CC(=CC2=C(C=1N1S(NC(C1)=O)(=O)=O)F)/C=C/C(=O)O QBOWEDKHENDSKU-VQHVLOKHSA-N 0.000 description 3
- VWOXWOVYEZJYNR-UHFFFAOYSA-N 1,6-dibromo-3-phenylmethoxynaphthalen-2-amine Chemical compound C(C1=CC=CC=C1)OC=1C(=C(C2=CC=C(C=C2C=1)Br)Br)N VWOXWOVYEZJYNR-UHFFFAOYSA-N 0.000 description 3
- PJLOFXYMEGBWIS-UHFFFAOYSA-N 1-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]acetyl]piperidine-4-carboxylic acid Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NCC(=O)N1CCC(CC1)C(=O)O)=O)=O PJLOFXYMEGBWIS-UHFFFAOYSA-N 0.000 description 3
- JTCCOWXCMLGMTJ-UHFFFAOYSA-N 1-[2-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]amino]acetyl]piperidine-4-carboxylic acid Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1)NCC(=O)N1CCC(CC1)C(=O)O)=O)=O JTCCOWXCMLGMTJ-UHFFFAOYSA-N 0.000 description 3
- QAXACDZGPZOBKL-UHFFFAOYSA-N 1-[2-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]oxy]acetyl]-N-[2-[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxyethyl]piperidine-4-carboxamide Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1)OCC(=O)N1CCC(CC1)C(=O)NCCOC1=CC2=C(C(=C(C=C2C=C1)O)N1S(NC(C1)=O)(=O)=O)F)=O)=O QAXACDZGPZOBKL-UHFFFAOYSA-N 0.000 description 3
- WPHHXAQXUQVEHH-UHFFFAOYSA-N 2,6-bis(phenylmethoxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound C(C1=CC=CC=C1)OC1=NC(=CC=C1B1OC(C(O1)(C)C)(C)C)OCC1=CC=CC=C1 WPHHXAQXUQVEHH-UHFFFAOYSA-N 0.000 description 3
- IREZYNKPQCIUME-UHFFFAOYSA-N 2,6-bis(phenylmethoxy)pyridine Chemical compound C=1C=CC=CC=1COC(N=1)=CC=CC=1OCC1=CC=CC=C1 IREZYNKPQCIUME-UHFFFAOYSA-N 0.000 description 3
- SFKUOMZBIWJCQN-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-(2-methylbut-3-yn-2-ylamino)isoindole-1,3-dione Chemical compound C#CC(C)(C)NC1=CC=CC=2C(=O)N(C(=O)C1=2)C1CCC(=O)NC1=O SFKUOMZBIWJCQN-UHFFFAOYSA-N 0.000 description 3
- UKLSNEYLHJEMPO-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-(prop-2-ynylamino)isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NCC#C)=O)=O UKLSNEYLHJEMPO-UHFFFAOYSA-N 0.000 description 3
- MPQLCQKBYRSPNA-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindole-1,3-dione Chemical compound O=C1C2=CC(F)=CC=C2C(=O)N1C1CCC(=O)NC1=O MPQLCQKBYRSPNA-UHFFFAOYSA-N 0.000 description 3
- VAGUFTJRKJFHAY-UHFFFAOYSA-N 2-[3-[[1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxobenzimidazol-5-yl]amino]azetidin-1-yl]-N-[5-fluoro-7-phenylmethoxy-6-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]acetamide Chemical compound C(C1=CC=CC=C1)OC1=C(C(=C2C=CC(=CC2=C1)NC(CN1CC(C1)NC1=CC2=C(N(C(N2C)=O)C2C(NC(CC2)=O)=O)C=C1)=O)F)N1S(NC(C1)=O)(=O)=O VAGUFTJRKJFHAY-UHFFFAOYSA-N 0.000 description 3
- PVBQKUPKDYBTHF-UHFFFAOYSA-N 2-[4-[1-(2,6-dioxopiperidin-3-yl)-2-oxo-3-propan-2-ylbenzimidazol-5-yl]piperidin-1-yl]-N-[5-fluoro-7-phenylmethoxy-6-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]acetamide Chemical compound C(C1=CC=CC=C1)OC1=C(C(=C2C=CC(=CC2=C1)NC(CN1CCC(CC1)C1=CC2=C(N(C(N2C(C)C)=O)C2C(NC(CC2)=O)=O)C=C1)=O)F)N1S(NC(C1)=O)(=O)=O PVBQKUPKDYBTHF-UHFFFAOYSA-N 0.000 description 3
- MLYWPVABLVVCOO-UHFFFAOYSA-N 2-[4-[1-(2,6-dioxopiperidin-3-yl)-2-oxobenzo[cd]indol-6-yl]piperidin-1-yl]-N-[2-[8-fluoro-6-phenylmethoxy-7-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxyethyl]acetamide Chemical compound C(C1=CC=CC=C1)OC=1C=C2C=CC(=CC2=C(C=1N1S(NC(C1)=O)(=O)=O)F)OCCNC(CN1CCC(CC1)C=1C=2C3=C(C(N(C3=CC=1)C1C(NC(CC1)=O)=O)=O)C=CC=2)=O MLYWPVABLVVCOO-UHFFFAOYSA-N 0.000 description 3
- XTDMYOQEUAYICO-UHFFFAOYSA-N 2-[4-[1-(2,6-dioxopiperidin-3-yl)-2-oxobenzo[cd]indol-6-yl]piperidin-1-yl]-N-[5-fluoro-7-phenylmethoxy-6-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]acetamide Chemical compound C(C1=CC=CC=C1)OC1=C(C(=C2C=CC(=CC2=C1)NC(CN1CCC(CC1)C=1C=2C3=C(C(N(C3=CC=1)C1C(NC(CC1)=O)=O)=O)C=CC=2)=O)F)N1S(NC(C1)=O)(=O)=O XTDMYOQEUAYICO-UHFFFAOYSA-N 0.000 description 3
- UZHRNFGTXVYNLO-UHFFFAOYSA-N 2-[4-[1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxobenzimidazol-4-yl]oxypiperidin-1-yl]acetic acid Chemical compound O=C1NC(CCC1N1C(N(C2=C1C=CC=C2OC1CCN(CC1)CC(=O)O)C)=O)=O UZHRNFGTXVYNLO-UHFFFAOYSA-N 0.000 description 3
- NBNJOICEMJWPKD-UHFFFAOYSA-N 2-[4-[3-(2,6-dioxopiperidin-3-yl)-1-methylindazol-6-yl]piperidin-1-yl]-N-[2-[8-fluoro-6-phenylmethoxy-7-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxyethyl]acetamide Chemical compound C(C1=CC=CC=C1)OC=1C=C2C=CC(=CC2=C(C=1N1S(NC(C1)=O)(=O)=O)F)OCCNC(CN1CCC(CC1)C1=CC=C2C(=NN(C2=C1)C)C1C(NC(CC1)=O)=O)=O NBNJOICEMJWPKD-UHFFFAOYSA-N 0.000 description 3
- KWQURVOUBMKEFZ-UHFFFAOYSA-N 2-[4-[3-(2,6-dioxopiperidin-3-yl)-1-methylindazol-6-yl]piperidin-1-yl]acetic acid Chemical compound O=C1NC(CCC1C1=NN(C2=CC(=CC=C12)C1CCN(CC1)CC(=O)O)C)=O KWQURVOUBMKEFZ-UHFFFAOYSA-N 0.000 description 3
- KSGHWAGSLYURJG-UHFFFAOYSA-N 2-chloro-N-[5-fluoro-7-phenylmethoxy-6-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]acetamide Chemical compound C(C1=CC=CC=C1)OC1=C(C(=C2C=CC(=CC2=C1)NC(CCl)=O)F)N1S(NC(C1)=O)(=O)=O KSGHWAGSLYURJG-UHFFFAOYSA-N 0.000 description 3
- HSIXXBCUADDVRA-UHFFFAOYSA-N 3-(1-methyl-6-piperidin-4-ylindazol-3-yl)piperidine-2,6-dione Chemical compound CN1N=C(C2=CC=C(C=C12)C1CCNCC1)C1C(NC(CC1)=O)=O HSIXXBCUADDVRA-UHFFFAOYSA-N 0.000 description 3
- RTKFITWDWCLYQH-UHFFFAOYSA-N 3-(2-oxo-5-piperidin-4-yl-3-propan-2-ylbenzimidazol-1-yl)piperidine-2,6-dione Chemical compound C(C)(C)N1C(N(C2=C1C=C(C=C2)C1CCNCC1)C1C(NC(CC1)=O)=O)=O RTKFITWDWCLYQH-UHFFFAOYSA-N 0.000 description 3
- BXDSZHDIOGCSPO-UHFFFAOYSA-N 3-(2-oxo-6-piperidin-4-yl-1,3-benzoxazol-3-yl)piperidine-2,6-dione Chemical compound O=C1OC2=C(N1C1C(NC(CC1)=O)=O)C=CC(=C2)C1CCNCC1 BXDSZHDIOGCSPO-UHFFFAOYSA-N 0.000 description 3
- XIMLVLBERFFABO-UHFFFAOYSA-N 3-(2-oxo-6-piperidin-4-ylbenzo[cd]indol-1-yl)piperidine-2,6-dione Chemical compound O=C1N(C2=CC=C(C=3C2=C1C=CC=3)C1CCNCC1)C1C(NC(CC1)=O)=O XIMLVLBERFFABO-UHFFFAOYSA-N 0.000 description 3
- NUBLSABJYRPFPB-UHFFFAOYSA-N 3-(3-fluoro-4-piperidin-4-ylanilino)piperidine-2,6-dione Chemical compound FC=1C=C(NC2C(NC(CC2)=O)=O)C=CC=1C1CCNCC1 NUBLSABJYRPFPB-UHFFFAOYSA-N 0.000 description 3
- LACNOZYZGMYRBL-UHFFFAOYSA-N 3-(3-oxo-6-prop-2-ynoxy-1H-isoindol-2-yl)piperidine-2,6-dione Chemical compound O=C1N(CC2=CC(=CC=C12)OCC#C)C1C(NC(CC1)=O)=O LACNOZYZGMYRBL-UHFFFAOYSA-N 0.000 description 3
- SFMZSBNKAJTONL-UHFFFAOYSA-N 3-(5-bromo-2-oxo-3-propan-2-ylbenzimidazol-1-yl)piperidine-2,6-dione Chemical compound BrC1=CC2=C(N(C(N2C(C)C)=O)C2C(NC(CC2)=O)=O)C=C1 SFMZSBNKAJTONL-UHFFFAOYSA-N 0.000 description 3
- CSPWBOBHCQNLLW-UHFFFAOYSA-N 3-(6-nitro-3-oxo-1h-isoindol-2-yl)piperidine-2,6-dione Chemical compound C1C2=CC([N+](=O)[O-])=CC=C2C(=O)N1C1CCC(=O)NC1=O CSPWBOBHCQNLLW-UHFFFAOYSA-N 0.000 description 3
- CCPYGERHHKUTDT-UHFFFAOYSA-N 3-[3-oxo-6-(prop-2-ynylamino)-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound O=C1N(CC2=CC(=CC=C12)NCC#C)C1C(NC(CC1)=O)=O CCPYGERHHKUTDT-UHFFFAOYSA-N 0.000 description 3
- BRWLBDCBNYXYCJ-UHFFFAOYSA-N 3-[4-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]oxymethyl]triazol-1-yl]-N-[5-fluoro-7-phenylmethoxy-6-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]propanamide Chemical compound C(C1=CC=CC=C1)OC1=C(C(=C2C=CC(=CC2=C1)NC(CCN1N=NC(=C1)COC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)=O)F)N1S(NC(C1)=O)(=O)=O BRWLBDCBNYXYCJ-UHFFFAOYSA-N 0.000 description 3
- FSNFVHRZSWSSPE-UHFFFAOYSA-N 3-[4-[[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]methyl]pyrazol-1-yl]propanoic acid Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NCC=1C=NN(C=1)CCC(=O)O)=O)=O FSNFVHRZSWSSPE-UHFFFAOYSA-N 0.000 description 3
- RLYSPNGKUULFFG-UHFFFAOYSA-N 3-[4-[[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]amino]methyl]pyrazol-1-yl]propanoic acid Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1)NCC=1C=NN(C=1)CCC(=O)O)=O)=O RLYSPNGKUULFFG-UHFFFAOYSA-N 0.000 description 3
- NHCSKRHTIVOWDZ-UHFFFAOYSA-N 3-[4-[[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]amino]methyl]pyrazol-1-yl]-N-[5-fluoro-7-phenylmethoxy-6-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]propanamide Chemical compound C(C1=CC=CC=C1)OC1=C(C(=C2C=CC(=CC2=C1)NC(CCN1N=CC(=C1)CNC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)=O)F)N1S(NC(C1)=O)(=O)=O NHCSKRHTIVOWDZ-UHFFFAOYSA-N 0.000 description 3
- CDGCWJMHXIOUSF-UHFFFAOYSA-N 3-[4-[[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]amino]methyl]triazol-1-yl]propanoic acid Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1)NCC=1N=NN(C=1)CCC(=O)O)=O)=O CDGCWJMHXIOUSF-UHFFFAOYSA-N 0.000 description 3
- MDJMDZHPCQOGFY-UHFFFAOYSA-N 3-[7-[2-(4-aminopiperidin-1-yl)-2-oxoethoxy]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound NC1CCN(CC1)C(COC1=C2CN(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O MDJMDZHPCQOGFY-UHFFFAOYSA-N 0.000 description 3
- BHPOOUUMRGOCIR-UHFFFAOYSA-N 3-bromo-2,6-bis(phenylmethoxy)pyridine Chemical compound N1=C(OCC=2C=CC=CC=2)C(Br)=CC=C1OCC1=CC=CC=C1 BHPOOUUMRGOCIR-UHFFFAOYSA-N 0.000 description 3
- BVQOQXXITQULGQ-UHFFFAOYSA-N 3-bromo-2-n-methylbenzene-1,2-diamine Chemical compound CNC1=C(N)C=CC=C1Br BVQOQXXITQULGQ-UHFFFAOYSA-N 0.000 description 3
- OXYJCZYMCDLXRM-UHFFFAOYSA-N 4-bromo-2-n-propan-2-ylbenzene-1,2-diamine Chemical compound CC(C)NC1=CC(Br)=CC=C1N OXYJCZYMCDLXRM-UHFFFAOYSA-N 0.000 description 3
- RTGYXYYWJABYDE-UHFFFAOYSA-N 4-bromo-3-methyl-1h-benzimidazol-2-one Chemical compound C1=CC=C2NC(=O)N(C)C2=C1Br RTGYXYYWJABYDE-UHFFFAOYSA-N 0.000 description 3
- KQMDQSYFJDDSIH-UHFFFAOYSA-N 5-(1-fluoro-7-hydroxy-3-phenylmethoxynaphthalen-2-yl)-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound C(C1=CC=CC=C1)OC=1C(=C(C2=CC(=CC=C2C=1)O)F)N1CC(NS1(=O)=O)=O KQMDQSYFJDDSIH-UHFFFAOYSA-N 0.000 description 3
- KUBDMTCJZPIZCQ-UHFFFAOYSA-N 5-[1-fluoro-3-phenylmethoxy-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-2-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound C(C1=CC=CC=C1)OC=1C(=C(C2=CC(=CC=C2C=1)B1OC(C(O1)(C)C)(C)C)F)N1CC(NS1(=O)=O)=O KUBDMTCJZPIZCQ-UHFFFAOYSA-N 0.000 description 3
- FASQPXTZYZCTMG-UHFFFAOYSA-N 5-bromo-2-nitro-n-propan-2-ylaniline Chemical compound CC(C)NC1=CC(Br)=CC=C1[N+]([O-])=O FASQPXTZYZCTMG-UHFFFAOYSA-N 0.000 description 3
- YPDNVCWGSMLWQL-UHFFFAOYSA-N 5-bromo-3-propan-2-yl-1h-benzimidazol-2-one Chemical compound BrC1=CC=C2NC(=O)N(C(C)C)C2=C1 YPDNVCWGSMLWQL-UHFFFAOYSA-N 0.000 description 3
- FTVGSRGPTYFWRQ-UHFFFAOYSA-N 5-bromo-n-methyl-2-nitroaniline Chemical compound CNC1=CC(Br)=CC=C1[N+]([O-])=O FTVGSRGPTYFWRQ-UHFFFAOYSA-N 0.000 description 3
- CTEZGWVTPDWNHB-UHFFFAOYSA-N 5-fluoro-7-phenylmethoxy-6-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalene-2-carboxylic acid Chemical compound C(C1=CC=CC=C1)OC1=C(C(=C2C=CC(=CC2=C1)C(=O)O)F)N1S(NC(C1)=O)(=O)=O CTEZGWVTPDWNHB-UHFFFAOYSA-N 0.000 description 3
- SGZUTVWSGJIMQL-UHFFFAOYSA-N 6-bromo-1-fluoro-3-phenylmethoxynaphthalen-2-amine Chemical compound C(C1=CC=CC=C1)OC=1C(=C(C2=CC=C(C=C2C=1)Br)F)N SGZUTVWSGJIMQL-UHFFFAOYSA-N 0.000 description 3
- AWNRAAVXFSTMQS-UHFFFAOYSA-N 6-bromo-1h-benzo[cd]indol-2-one Chemical compound N1C(=O)C2=CC=CC3=C2C1=CC=C3Br AWNRAAVXFSTMQS-UHFFFAOYSA-N 0.000 description 3
- WRDMLDTWGJDYTF-UHFFFAOYSA-N 6-bromo-3-phenylmethoxynaphthalen-2-amine Chemical compound C(C1=CC=CC=C1)OC=1C(=CC2=CC=C(C=C2C=1)Br)N WRDMLDTWGJDYTF-UHFFFAOYSA-N 0.000 description 3
- IMKZNQCYEVCERT-UHFFFAOYSA-N 7-bromo-1-fluoro-3-phenylmethoxynaphthalen-2-amine Chemical compound C(C1=CC=CC=C1)OC=1C(=C(C2=CC(=CC=C2C=1)Br)F)N IMKZNQCYEVCERT-UHFFFAOYSA-N 0.000 description 3
- CEVINNCNSDABMT-UHFFFAOYSA-N 7-bromo-3-phenylmethoxynaphthalen-2-amine Chemical compound C(C1=CC=CC=C1)OC=1C(=CC2=CC(=CC=C2C=1)Br)N CEVINNCNSDABMT-UHFFFAOYSA-N 0.000 description 3
- BOAOKYPHSCMSEW-UHFFFAOYSA-N 7-bromo-3-phenylmethoxynaphthalene-2-carboxylic acid Chemical compound C(C1=CC=CC=C1)OC=1C(=CC2=CC(=CC=C2C=1)Br)C(=O)O BOAOKYPHSCMSEW-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- ASPBNCYMQGKLBA-UHFFFAOYSA-N BrC1=CC2=C(N(C(O2)=O)C2C(NC(CC2)=O)=O)C=C1 Chemical compound BrC1=CC2=C(N(C(O2)=O)C2C(NC(CC2)=O)=O)C=C1 ASPBNCYMQGKLBA-UHFFFAOYSA-N 0.000 description 3
- RMODNRAIBFTCEC-UHFFFAOYSA-N BrC1=CC=CC=2N(C(N(C=21)C)=O)C1C(NC(CC1)=O)=O Chemical compound BrC1=CC=CC=2N(C(N(C=21)C)=O)C1C(NC(CC1)=O)=O RMODNRAIBFTCEC-UHFFFAOYSA-N 0.000 description 3
- UILJPCUGTZVVPA-UHFFFAOYSA-N C(C1=CC=CC=C1)OC=1C=C2C=CC(=CC2=C(C=1N1S(NC(C1)=O)(=O)=O)F)C=CC(=O)NC1CCN(CC1)C(COC1=C2CN(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O Chemical compound C(C1=CC=CC=C1)OC=1C=C2C=CC(=CC2=C(C=1N1S(NC(C1)=O)(=O)=O)F)C=CC(=O)NC1CCN(CC1)C(COC1=C2CN(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O UILJPCUGTZVVPA-UHFFFAOYSA-N 0.000 description 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 3
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 3
- ADYDACKHUCSBDP-UHFFFAOYSA-N CN1C(N(C2=C1C(=CC=C2)C1CCNCC1)C1C(NC(CC1)=O)=O)=O Chemical compound CN1C(N(C2=C1C(=CC=C2)C1CCNCC1)C1C(NC(CC1)=O)=O)=O ADYDACKHUCSBDP-UHFFFAOYSA-N 0.000 description 3
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 description 3
- XNNUKBPLAWFJDE-UHFFFAOYSA-N N-(7-bromo-1-fluoro-3-phenylmethoxynaphthalen-2-yl)-2,2,2-trifluoroacetamide Chemical compound C(C1=CC=CC=C1)OC=1C(=C(C2=CC(=CC=C2C=1)Br)F)NC(C(F)(F)F)=O XNNUKBPLAWFJDE-UHFFFAOYSA-N 0.000 description 3
- OFDAKHHJTBALCY-UHFFFAOYSA-N O=C1N(CC2=C(C=CC=C12)OCC#C)C1C(NC(CC1)=O)=O Chemical compound O=C1N(CC2=C(C=CC=C12)OCC#C)C1C(NC(CC1)=O)=O OFDAKHHJTBALCY-UHFFFAOYSA-N 0.000 description 3
- GUFOJKMEAHGAEO-UHFFFAOYSA-N O=C1NC(CCC1N1C(C2=C3C(C(=CC=C13)C1CCN(CC1)C(=O)OC(C)(C)C)=CC=C2)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=C3C(C(=CC=C13)C1CCN(CC1)C(=O)OC(C)(C)C)=CC=C2)=O)=O GUFOJKMEAHGAEO-UHFFFAOYSA-N 0.000 description 3
- GZDHFXSZORAMRL-UHFFFAOYSA-N O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)NCC#C)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)NCC#C)=O)=O GZDHFXSZORAMRL-UHFFFAOYSA-N 0.000 description 3
- ZWBZZVNRJSTAAM-UHFFFAOYSA-N O=C1NC(CCC1N1C(N(C2=C1C=CC(=C2)C1CCN(CC1)CCC(=O)O)C)=O)=O Chemical compound O=C1NC(CCC1N1C(N(C2=C1C=CC(=C2)C1CCN(CC1)CCC(=O)O)C)=O)=O ZWBZZVNRJSTAAM-UHFFFAOYSA-N 0.000 description 3
- XQQMIGIZRQWSQT-UHFFFAOYSA-N O=C1NC(CCC1N1C(N(C2=C1C=CC(=C2)C1CCN(CC1)CCC(=O)OC(C)(C)C)C)=O)=O Chemical compound O=C1NC(CCC1N1C(N(C2=C1C=CC(=C2)C1CCN(CC1)CCC(=O)OC(C)(C)C)C)=O)=O XQQMIGIZRQWSQT-UHFFFAOYSA-N 0.000 description 3
- KCXCWAQDEUHXIJ-UHFFFAOYSA-N O=C1NC(CCC1N1C(N(C2=C1C=CC=C2C1CCN(CC1)C(=O)OC(C)(C)C)C)=O)=O Chemical compound O=C1NC(CCC1N1C(N(C2=C1C=CC=C2C1CCN(CC1)C(=O)OC(C)(C)C)C)=O)=O KCXCWAQDEUHXIJ-UHFFFAOYSA-N 0.000 description 3
- VLPJXCJBCOTMCF-UHFFFAOYSA-N O=C1NC2=CC=C(C=3C2=C1C=CC=3)C1CCN(CC1)C(=O)OC(C)(C)C Chemical compound O=C1NC2=CC=C(C=3C2=C1C=CC=3)C1CCN(CC1)C(=O)OC(C)(C)C VLPJXCJBCOTMCF-UHFFFAOYSA-N 0.000 description 3
- SYAUDTROBWZVLH-UHFFFAOYSA-N O=C1NC2=CC=C(C=3C2=C1C=CC=3)C=1CCN(CC=1)C(=O)OC(C)(C)C Chemical compound O=C1NC2=CC=C(C=3C2=C1C=CC=3)C=1CCN(CC=1)C(=O)OC(C)(C)C SYAUDTROBWZVLH-UHFFFAOYSA-N 0.000 description 3
- MLRBTGIZSNUSJD-UHFFFAOYSA-N O=S1(N(CC(N1)=O)C=1C(=C2C=CC(=CC2=CC=1O)NC(OC(C)(C)C)=O)F)=O Chemical compound O=S1(N(CC(N1)=O)C=1C(=C2C=CC(=CC2=CC=1O)NC(OC(C)(C)C)=O)F)=O MLRBTGIZSNUSJD-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 235000019257 ammonium acetate Nutrition 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- ZUFOYNADIXXFAT-UHFFFAOYSA-N benzyl 7-bromo-3-phenylmethoxynaphthalene-2-carboxylate Chemical compound C(C1=CC=CC=C1)OC=1C(=CC2=CC(=CC=C2C=1)Br)C(=O)OCC1=CC=CC=C1 ZUFOYNADIXXFAT-UHFFFAOYSA-N 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- XJHCXCQVJFPJIK-UHFFFAOYSA-M cesium fluoride Substances [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 3
- 239000003610 charcoal Substances 0.000 description 3
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- MXFYYFVVIIWKFE-UHFFFAOYSA-N dicyclohexyl-[2-[2,6-di(propan-2-yloxy)phenyl]phenyl]phosphane Chemical compound CC(C)OC1=CC=CC(OC(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 MXFYYFVVIIWKFE-UHFFFAOYSA-N 0.000 description 3
- 230000002222 downregulating effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 230000005746 immune checkpoint blockade Effects 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 3
- XAQBRMOPXLRXBB-UHFFFAOYSA-N methyl 2-(bromomethyl)-4-hydroxybenzoate Chemical compound COC(=O)C1=CC=C(O)C=C1CBr XAQBRMOPXLRXBB-UHFFFAOYSA-N 0.000 description 3
- PGNKFDOPHHNVNF-UHFFFAOYSA-N methyl 2-(bromomethyl)-4-nitrobenzoate Chemical compound COC(=O)C1=CC=C([N+]([O-])=O)C=C1CBr PGNKFDOPHHNVNF-UHFFFAOYSA-N 0.000 description 3
- YLZDVZIVSTZAEQ-UHFFFAOYSA-N methyl 2-(bromomethyl)-4-prop-2-ynoxybenzoate Chemical compound BrCC1=C(C(=O)OC)C=CC(=C1)OCC#C YLZDVZIVSTZAEQ-UHFFFAOYSA-N 0.000 description 3
- UAWHOBZNABPCFL-UHFFFAOYSA-N methyl 2-[(6-bromo-1-fluoro-3-phenylmethoxynaphthalen-2-yl)-[(2-methylpropan-2-yl)oxycarbonylsulfamoyl]amino]acetate Chemical compound C(C1=CC=CC=C1)OC=1C(=C(C2=CC=C(C=C2C=1)Br)F)N(S(NC(=O)OC(C)(C)C)(=O)=O)CC(=O)OC UAWHOBZNABPCFL-UHFFFAOYSA-N 0.000 description 3
- LNMIPHHGQJKMLU-UHFFFAOYSA-N methyl 2-[(6-bromo-1-fluoro-3-phenylmethoxynaphthalen-2-yl)-sulfamoylamino]acetate Chemical compound C(C1=CC=CC=C1)OC=1C(=C(C2=CC=C(C=C2C=1)Br)F)N(S(N)(=O)=O)CC(=O)OC LNMIPHHGQJKMLU-UHFFFAOYSA-N 0.000 description 3
- LFNKCFFGOOFGDL-UHFFFAOYSA-N methyl 2-[(6-bromo-1-fluoro-3-phenylmethoxynaphthalen-2-yl)amino]acetate Chemical compound C(C1=CC=CC=C1)OC=1C(=C(C2=CC=C(C=C2C=1)Br)F)NCC(=O)OC LFNKCFFGOOFGDL-UHFFFAOYSA-N 0.000 description 3
- UDTYIJXTPMJTLH-UHFFFAOYSA-N methyl 2-[(7-bromo-1-fluoro-3-phenylmethoxynaphthalen-2-yl)-(2,2,2-trifluoroacetyl)amino]acetate Chemical compound C(C1=CC=CC=C1)OC=1C(=C(C2=CC(=CC=C2C=1)Br)F)N(C(C(F)(F)F)=O)CC(=O)OC UDTYIJXTPMJTLH-UHFFFAOYSA-N 0.000 description 3
- ZBKPMUPSUACYSI-UHFFFAOYSA-N methyl 2-[(7-bromo-1-fluoro-3-phenylmethoxynaphthalen-2-yl)-[(2-methylpropan-2-yl)oxycarbonylsulfamoyl]amino]acetate Chemical compound C(C1=CC=CC=C1)OC=1C(=C(C2=CC(=CC=C2C=1)Br)F)N(CC(=O)OC)S(NC(=O)OC(C)(C)C)(=O)=O ZBKPMUPSUACYSI-UHFFFAOYSA-N 0.000 description 3
- CKRHCJSHABTVAN-UHFFFAOYSA-N methyl 2-[(7-bromo-1-fluoro-3-phenylmethoxynaphthalen-2-yl)-sulfamoylamino]acetate Chemical compound C(C1=CC=CC=C1)OC=1C(=C(C2=CC(=CC=C2C=1)Br)F)N(S(N)(=O)=O)CC(=O)OC CKRHCJSHABTVAN-UHFFFAOYSA-N 0.000 description 3
- ILELVZHFXPMSQP-UHFFFAOYSA-N methyl 2-[(7-bromo-1-fluoro-3-phenylmethoxynaphthalen-2-yl)amino]acetate Chemical compound COC(=O)CNC1=C(F)C2=CC(Br)=CC=C2C=C1OCC1=CC=CC=C1 ILELVZHFXPMSQP-UHFFFAOYSA-N 0.000 description 3
- GMDQVYSJRIUJFK-UHFFFAOYSA-N methyl 4-acetyloxy-2-(bromomethyl)benzoate Chemical compound COC(=O)C1=CC=C(OC(C)=O)C=C1CBr GMDQVYSJRIUJFK-UHFFFAOYSA-N 0.000 description 3
- ORMRPAACCDDYRY-UHFFFAOYSA-N methyl 4-acetyloxy-2-methylbenzoate Chemical compound COC(=O)C1=CC=C(OC(C)=O)C=C1C ORMRPAACCDDYRY-UHFFFAOYSA-N 0.000 description 3
- XPYCFEAZKHVWMA-UHFFFAOYSA-N methyl 5-fluoro-7-phenylmethoxy-6-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalene-2-carboxylate Chemical compound C(C1=CC=CC=C1)OC1=C(C(=C2C=CC(=CC2=C1)C(=O)OC)F)N1S(NC(C1)=O)(=O)=O XPYCFEAZKHVWMA-UHFFFAOYSA-N 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000001715 oxadiazolyl group Chemical group 0.000 description 3
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 3
- 235000010378 sodium ascorbate Nutrition 0.000 description 3
- 229960005055 sodium ascorbate Drugs 0.000 description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 3
- 241000894007 species Species 0.000 description 3
- TXSWSZPOTDRHGU-UHFFFAOYSA-N tert-butyl 1-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]acetyl]piperidine-4-carboxylate Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NCC(=O)N1CCC(CC1)C(=O)OC(C)(C)C)=O)=O TXSWSZPOTDRHGU-UHFFFAOYSA-N 0.000 description 3
- FYBGLVXZBBTDJE-UHFFFAOYSA-N tert-butyl 1-[2-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]amino]acetyl]piperidine-4-carboxylate Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1)NCC(=O)N1CCC(CC1)C(=O)OC(C)(C)C)=O)=O FYBGLVXZBBTDJE-UHFFFAOYSA-N 0.000 description 3
- VPHODJJPAXISOE-UHFFFAOYSA-N tert-butyl 2-[4-[1-(2,6-dioxopiperidin-3-yl)-2-oxo-3-propan-2-ylbenzimidazol-5-yl]piperidin-1-yl]acetate Chemical compound O=C1NC(CCC1N1C(N(C2=C1C=CC(=C2)C1CCN(CC1)CC(=O)OC(C)(C)C)C(C)C)=O)=O VPHODJJPAXISOE-UHFFFAOYSA-N 0.000 description 3
- RQVCYHCEXXEDJA-UHFFFAOYSA-N tert-butyl 2-[4-[1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxobenzimidazol-4-yl]oxypiperidin-1-yl]acetate Chemical compound O=C1NC(CCC1N1C(N(C2=C1C=CC=C2OC1CCN(CC1)CC(=O)OC(C)(C)C)C)=O)=O RQVCYHCEXXEDJA-UHFFFAOYSA-N 0.000 description 3
- VXYXKVVHOOQYDK-UHFFFAOYSA-N tert-butyl 2-[4-[1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxobenzimidazol-5-yl]piperidin-1-yl]acetate Chemical compound O=C1NC(CCC1N1C(N(C2=C1C=CC(=C2)C1CCN(CC1)CC(=O)OC(C)(C)C)C)=O)=O VXYXKVVHOOQYDK-UHFFFAOYSA-N 0.000 description 3
- GTBDCRHUDGWJGX-UHFFFAOYSA-N tert-butyl 2-[4-[4-[(2,6-dioxopiperidin-3-yl)amino]-2-fluorophenyl]piperidin-1-yl]acetate Chemical compound O=C1NC(CCC1NC1=CC(=C(C=C1)C1CCN(CC1)CC(=O)OC(C)(C)C)F)=O GTBDCRHUDGWJGX-UHFFFAOYSA-N 0.000 description 3
- CBSCIRQGLJGNLM-UHFFFAOYSA-N tert-butyl 3-(4-formylpyrazol-1-yl)propanoate Chemical compound C(=O)C=1C=NN(C=1)CCC(=O)OC(C)(C)C CBSCIRQGLJGNLM-UHFFFAOYSA-N 0.000 description 3
- FHBXKVNLWZYDSA-UHFFFAOYSA-N tert-butyl 3-[4-(hydroxymethyl)pyrazol-1-yl]propanoate Chemical compound OCC=1C=NN(C=1)CCC(=O)OC(C)(C)C FHBXKVNLWZYDSA-UHFFFAOYSA-N 0.000 description 3
- PDUWZNYYNGYQOW-UHFFFAOYSA-N tert-butyl 3-[4-(methylsulfonyloxymethyl)pyrazol-1-yl]propanoate Chemical compound CS(=O)(=O)OCC=1C=NN(C=1)CCC(=O)OC(C)(C)C PDUWZNYYNGYQOW-UHFFFAOYSA-N 0.000 description 3
- JJPFHBQIUFQZFA-UHFFFAOYSA-N tert-butyl 3-[4-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]oxymethyl]pyrazol-1-yl]propanoate Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1)OCC=1C=NN(C=1)CCC(=O)OC(C)(C)C)=O)=O JJPFHBQIUFQZFA-UHFFFAOYSA-N 0.000 description 3
- FTZMPVBYWJQWJF-UHFFFAOYSA-N tert-butyl 3-[4-[[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]methyl]triazol-1-yl]azetidine-1-carboxylate Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NCC=1N=NN(C=1)C1CN(C1)C(=O)OC(C)(C)C)=O)=O FTZMPVBYWJQWJF-UHFFFAOYSA-N 0.000 description 3
- KJUOMYOUJGKYED-UHFFFAOYSA-N tert-butyl 3-[[1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxobenzimidazol-5-yl]amino]azetidine-1-carboxylate Chemical compound O=C1NC(CCC1N1C(N(C2=C1C=CC(=C2)NC1CN(C1)C(=O)OC(C)(C)C)C)=O)=O KJUOMYOUJGKYED-UHFFFAOYSA-N 0.000 description 3
- ZHQJKBCCOFSQEM-UHFFFAOYSA-N tert-butyl 3-azidoazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(N=[N+]=[N-])C1 ZHQJKBCCOFSQEM-UHFFFAOYSA-N 0.000 description 3
- XXBDTKYKFFIAEY-UHFFFAOYSA-N tert-butyl 3-methylsulfonyloxyazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(OS(C)(=O)=O)C1 XXBDTKYKFFIAEY-UHFFFAOYSA-N 0.000 description 3
- QKCPFTAJTPDBML-UHFFFAOYSA-N tert-butyl 4-(3-methyl-2-oxo-1H-benzimidazol-5-yl)piperidine-1-carboxylate Chemical compound CN1C(NC2=C1C=C(C=C2)C1CCN(CC1)C(=O)OC(C)(C)C)=O QKCPFTAJTPDBML-UHFFFAOYSA-N 0.000 description 3
- SGWGUQJARHMANT-UHFFFAOYSA-N tert-butyl 4-(4-amino-2-fluorophenyl)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC(C=2C(=CC(N)=CC=2)F)=C1 SGWGUQJARHMANT-UHFFFAOYSA-N 0.000 description 3
- VZFKHOHBGFOUCN-UHFFFAOYSA-N tert-butyl 4-[1-(2,6-dioxopiperidin-3-yl)-2-oxo-3-propan-2-ylbenzimidazol-5-yl]-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound O=C1NC(CCC1N1C(N(C2=C1C=CC(=C2)C=1CCN(CC=1)C(=O)OC(C)(C)C)C(C)C)=O)=O VZFKHOHBGFOUCN-UHFFFAOYSA-N 0.000 description 3
- MXGMWUJGDQXVIK-UHFFFAOYSA-N tert-butyl 4-[1-(2,6-dioxopiperidin-3-yl)-2-oxo-3-propan-2-ylbenzimidazol-5-yl]piperidine-1-carboxylate Chemical compound O=C1NC(CCC1N1C(N(C2=C1C=CC(=C2)C1CCN(CC1)C(=O)OC(C)(C)C)C(C)C)=O)=O MXGMWUJGDQXVIK-UHFFFAOYSA-N 0.000 description 3
- SWANQGPNQCMGIS-UHFFFAOYSA-N tert-butyl 4-[1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxobenzimidazol-4-yl]oxypiperidine-1-carboxylate Chemical compound O=C1NC(CCC1N1C(N(C2=C1C=CC=C2OC1CCN(CC1)C(=O)OC(C)(C)C)C)=O)=O SWANQGPNQCMGIS-UHFFFAOYSA-N 0.000 description 3
- QYQWUWIGYTUNNH-UHFFFAOYSA-N tert-butyl 4-[3-(2,6-dioxopiperidin-3-yl)-2-oxo-1,3-benzoxazol-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound O=C1NC(CCC1N1C(OC2=C1C=CC(=C2)C=1CCN(CC=1)C(=O)OC(C)(C)C)=O)=O QYQWUWIGYTUNNH-UHFFFAOYSA-N 0.000 description 3
- RBTWOUZVEWUFDA-UHFFFAOYSA-N tert-butyl 4-[3-(2,6-dioxopiperidin-3-yl)-2-oxo-1,3-benzoxazol-6-yl]piperidine-1-carboxylate Chemical compound O=C1NC(CCC1N1C(OC2=C1C=CC(=C2)C1CCN(CC1)C(=O)OC(C)(C)C)=O)=O RBTWOUZVEWUFDA-UHFFFAOYSA-N 0.000 description 3
- PIVQQEGVOJRUQU-UHFFFAOYSA-N tert-butyl 4-[3-(methylamino)-4-nitrophenyl]-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound CNC=1C=C(C=CC=1[N+](=O)[O-])C=1CCN(CC=1)C(=O)OC(C)(C)C PIVQQEGVOJRUQU-UHFFFAOYSA-N 0.000 description 3
- NTCWWAMTCKOQCB-UHFFFAOYSA-N tert-butyl 4-[3-[2,6-bis(phenylmethoxy)pyridin-3-yl]-1-methylindazol-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound C(C1=CC=CC=C1)OC1=NC(=CC=C1C1=NN(C2=CC(=CC=C12)C=1CCN(CC=1)C(=O)OC(C)(C)C)C)OCC1=CC=CC=C1 NTCWWAMTCKOQCB-UHFFFAOYSA-N 0.000 description 3
- UNIAEKPSHZFHLK-UHFFFAOYSA-N tert-butyl 4-[4-[(2,6-dioxopiperidin-3-yl)amino]-2-fluorophenyl]piperidine-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)C1=C(C=C(C=C1)NC1C(NC(CC1)=O)=O)F UNIAEKPSHZFHLK-UHFFFAOYSA-N 0.000 description 3
- XXHFDSARUZMZDH-UHFFFAOYSA-N tert-butyl 4-[4-amino-3-(methylamino)phenyl]piperidine-1-carboxylate Chemical compound NC1=C(C=C(C=C1)C1CCN(CC1)C(=O)OC(C)(C)C)NC XXHFDSARUZMZDH-UHFFFAOYSA-N 0.000 description 3
- ZJMWLHCDNBDQGK-UHFFFAOYSA-N tert-butyl N-[1-[2-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]oxy]acetyl]piperidin-4-yl]carbamate Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1)OCC(=O)N1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O ZJMWLHCDNBDQGK-UHFFFAOYSA-N 0.000 description 3
- CFGGVXSKHUOPJW-UHFFFAOYSA-N tert-butyl N-[2-[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxyethyl]carbamate Chemical compound O=S1(N(CC(N1)=O)C1=C(C=C2C=CC(=CC2=C1F)OCCNC(OC(C)(C)C)=O)O)=O CFGGVXSKHUOPJW-UHFFFAOYSA-N 0.000 description 3
- MEMDVKRJKVBSNQ-UHFFFAOYSA-N tert-butyl n-(7-bromo-3-phenylmethoxynaphthalen-2-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC2=CC(Br)=CC=C2C=C1OCC1=CC=CC=C1 MEMDVKRJKVBSNQ-UHFFFAOYSA-N 0.000 description 3
- VLFRGIAACOBTLR-UHFFFAOYSA-N tert-butyl piperidine-4-carboxylate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)C1CCNCC1 VLFRGIAACOBTLR-UHFFFAOYSA-N 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 2
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 description 2
- NDTPPUZPHDEZFV-UHFFFAOYSA-N 1-N-[2,6-bis(phenylmethoxy)pyridin-3-yl]-4-bromo-2-N-methylbenzene-1,2-diamine Chemical compound BrC=1C=C(C(=CC=1)NC=1C(=NC(=CC=1)OCC1=CC=CC=C1)OCC1=CC=CC=C1)NC NDTPPUZPHDEZFV-UHFFFAOYSA-N 0.000 description 2
- ZYOJRECHAIXHKW-UHFFFAOYSA-N 1-[2-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]oxy]acetyl]piperidine-4-carboxylic acid Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1)OCC(=O)N1CCC(CC1)C(=O)O)=O)=O ZYOJRECHAIXHKW-UHFFFAOYSA-N 0.000 description 2
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 2
- LRGBDJBDJXZTTD-UHFFFAOYSA-N 1h-pyrazole-4-carbaldehyde Chemical compound O=CC=1C=NNC=1 LRGBDJBDJXZTTD-UHFFFAOYSA-N 0.000 description 2
- LOKYAWRCHORJDQ-UHFFFAOYSA-N 2,6-bis(phenylmethoxy)pyridin-3-amine Chemical compound N1=C(OCC=2C=CC=CC=2)C(N)=CC=C1OCC1=CC=CC=C1 LOKYAWRCHORJDQ-UHFFFAOYSA-N 0.000 description 2
- CRAUTELYXAAAPW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindole-1,3-dione Chemical compound O=C1C=2C(F)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O CRAUTELYXAAAPW-UHFFFAOYSA-N 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- WJZXODCLCFQYLF-UHFFFAOYSA-N 2-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]oxy]acetic acid Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1)OCC(=O)O)=O)=O WJZXODCLCFQYLF-UHFFFAOYSA-N 0.000 description 2
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 2
- YCPULGHBTPQLRH-UHFFFAOYSA-N 3-aminopiperidine-2,6-dione;hydron;chloride Chemical compound Cl.NC1CCC(=O)NC1=O YCPULGHBTPQLRH-UHFFFAOYSA-N 0.000 description 2
- VQCWSOYHHXXWSP-UHFFFAOYSA-N 4-bromo-2-fluoro-1-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(Br)C=C1F VQCWSOYHHXXWSP-UHFFFAOYSA-N 0.000 description 2
- XZWXQSGFZHRDNB-UHFFFAOYSA-N 7-bromo-3-hydroxynaphthalene-2-carboxylic acid Chemical compound BrC1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 XZWXQSGFZHRDNB-UHFFFAOYSA-N 0.000 description 2
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- 102000008096 B7-H1 Antigen Human genes 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 2
- 108091033409 CRISPR Proteins 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 2
- 102100036721 Insulin receptor Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 2
- 102000006814 Non-Receptor Protein Tyrosine Phosphatases Human genes 0.000 description 2
- 108010086748 Non-Receptor Protein Tyrosine Phosphatases Proteins 0.000 description 2
- 108010015832 Non-Receptor Type 2 Protein Tyrosine Phosphatase Proteins 0.000 description 2
- VCDIDLSCUWYXNS-UHFFFAOYSA-N O=C1NC(CCC1N1C(N(C2=C1C=CC(=C2)C1CCN(CC1)C(=O)OC(C)(C)C)C)=O)=O Chemical compound O=C1NC(CCC1N1C(N(C2=C1C=CC(=C2)C1CCN(CC1)C(=O)OC(C)(C)C)C)=O)=O VCDIDLSCUWYXNS-UHFFFAOYSA-N 0.000 description 2
- CEEGGUZBDXLBJU-UHFFFAOYSA-N O=C1NC(CCC1N1C(N(C2=C1C=CC=C2C=1CCN(CC=1)C(=O)OC(C)(C)C)C)=O)=O Chemical compound O=C1NC(CCC1N1C(N(C2=C1C=CC=C2C=1CCN(CC=1)C(=O)OC(C)(C)C)C)=O)=O CEEGGUZBDXLBJU-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 108010087946 PROTAC-3 Proteins 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 101150001354 Ptpn2 gene Proteins 0.000 description 2
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 2
- 102000006381 STAT1 Transcription Factor Human genes 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 2
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 2
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 2
- 102000044159 Ubiquitin Human genes 0.000 description 2
- 108090000848 Ubiquitin Proteins 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 230000005587 bubbling Effects 0.000 description 2
- 238000002619 cancer immunotherapy Methods 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- WRJWRGBVPUUDLA-UHFFFAOYSA-N chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229910000365 copper sulfate Inorganic materials 0.000 description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000001064 degrader Substances 0.000 description 2
- RJGHQTVXGKYATR-UHFFFAOYSA-L dibutyl(dichloro)stannane Chemical compound CCCC[Sn](Cl)(Cl)CCCC RJGHQTVXGKYATR-UHFFFAOYSA-L 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
- 125000005956 isoquinolyl group Chemical group 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 2
- FINKSGWSBJRISB-UHFFFAOYSA-N methyl 4-methoxy-2-methylbenzoate Natural products COC(=O)C1=CC=C(O)C=C1C FINKSGWSBJRISB-UHFFFAOYSA-N 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- RLKHFSNWQCZBDC-UHFFFAOYSA-N n-(benzenesulfonyl)-n-fluorobenzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)N(F)S(=O)(=O)C1=CC=CC=C1 RLKHFSNWQCZBDC-UHFFFAOYSA-N 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 2
- PARWUHTVGZSQPD-UHFFFAOYSA-N phenylsilane Chemical compound [SiH3]C1=CC=CC=C1 PARWUHTVGZSQPD-UHFFFAOYSA-N 0.000 description 2
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- JKANAVGODYYCQF-UHFFFAOYSA-N prop-2-yn-1-amine Chemical compound NCC#C JKANAVGODYYCQF-UHFFFAOYSA-N 0.000 description 2
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- PODWXQQNRWNDGD-UHFFFAOYSA-L sodium thiosulfate pentahydrate Chemical compound O.O.O.O.O.[Na+].[Na+].[O-]S([S-])(=O)=O PODWXQQNRWNDGD-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- AEJQFQFDDIZLTC-ZRDIBKRKSA-N tert-butyl (E)-3-[8-fluoro-6-phenylmethoxy-7-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]prop-2-enoate Chemical compound C(C1=CC=CC=C1)OC=1C=C2C=CC(=CC2=C(C=1N1S(NC(C1)=O)(=O)=O)F)/C=C/C(=O)OC(C)(C)C AEJQFQFDDIZLTC-ZRDIBKRKSA-N 0.000 description 2
- MDJVNDZGACOPMF-UHFFFAOYSA-N tert-butyl 1-[2-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]oxy]acetyl]piperidine-4-carboxylate Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1)OCC(=O)N1CCC(CC1)C(=O)OC(C)(C)C)=O)=O MDJVNDZGACOPMF-UHFFFAOYSA-N 0.000 description 2
- LPYSSCVDKVVGFA-UHFFFAOYSA-N tert-butyl 2-[4-[1-(2,6-dioxopiperidin-3-yl)-2-oxobenzo[cd]indol-6-yl]piperidin-1-yl]acetate Chemical compound O=C1NC(CCC1N1C(C2=C3C(C(=CC=C13)C1CCN(CC1)CC(=O)OC(C)(C)C)=CC=C2)=O)=O LPYSSCVDKVVGFA-UHFFFAOYSA-N 0.000 description 2
- FWFSHNKESQZLKA-UHFFFAOYSA-N tert-butyl 2-[4-[3-(2,6-dioxopiperidin-3-yl)-1-methylindazol-6-yl]piperidin-1-yl]acetate Chemical compound O=C1NC(CCC1C1=NN(C2=CC(=CC=C12)C1CCN(CC1)CC(=O)OC(C)(C)C)C)=O FWFSHNKESQZLKA-UHFFFAOYSA-N 0.000 description 2
- MYOKQRDVUOAJES-UHFFFAOYSA-N tert-butyl 2-[4-[3-(2,6-dioxopiperidin-3-yl)-2-oxo-1,3-benzoxazol-6-yl]piperidin-1-yl]acetate Chemical compound O=C1NC(CCC1N1C(OC2=C1C=CC(=C2)C1CCN(CC1)CC(=O)OC(C)(C)C)=O)=O MYOKQRDVUOAJES-UHFFFAOYSA-N 0.000 description 2
- RMWVUWLBLWBQDS-UHFFFAOYSA-N tert-butyl 3-bromopropanoate Chemical compound CC(C)(C)OC(=O)CCBr RMWVUWLBLWBQDS-UHFFFAOYSA-N 0.000 description 2
- BEROWKNZEWSWTQ-UHFFFAOYSA-N tert-butyl 4-(3-iodo-1-methylindazol-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound IC1=NN(C2=CC(=CC=C12)C=1CCN(CC=1)C(=O)OC(C)(C)C)C BEROWKNZEWSWTQ-UHFFFAOYSA-N 0.000 description 2
- XCRAIXIYAAKLOC-UHFFFAOYSA-N tert-butyl 4-[4-[[2,6-bis(phenylmethoxy)pyridin-3-yl]amino]-2-fluorophenyl]-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1CCC(=CC1)C1=C(C=C(C=C1)NC=1C(=NC(=CC=1)OCC1=CC=CC=C1)OCC1=CC=CC=C1)F XCRAIXIYAAKLOC-UHFFFAOYSA-N 0.000 description 2
- ZVVCHMYOHXMVDY-UHFFFAOYSA-N tert-butyl N-(2-amino-6-bromophenyl)-N-methylcarbamate Chemical compound NC1=C(C(=CC=C1)Br)N(C(OC(C)(C)C)=O)C ZVVCHMYOHXMVDY-UHFFFAOYSA-N 0.000 description 2
- UQQHRBZKVOUUBP-UHFFFAOYSA-N tert-butyl N-(2-bromo-6-nitrophenyl)-N-methylcarbamate Chemical compound BrC1=C(C(=CC=C1)[N+](=O)[O-])N(C(OC(C)(C)C)=O)C UQQHRBZKVOUUBP-UHFFFAOYSA-N 0.000 description 2
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000004306 triazinyl group Chemical group 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 230000034512 ubiquitination Effects 0.000 description 2
- 238000010798 ubiquitination Methods 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 description 1
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- CXVQBQBGHUDVBP-UHFFFAOYSA-N 1-[2,6-bis(phenylmethoxy)pyridin-3-yl]-4-bromo-3-methylbenzimidazol-2-one Chemical compound BrC1=CC=CC=2N(C(N(C=21)C)=O)C=1C(=NC(=CC=1)OCC1=CC=CC=C1)OCC1=CC=CC=C1 CXVQBQBGHUDVBP-UHFFFAOYSA-N 0.000 description 1
- DFKWGHKQFSKDDL-UHFFFAOYSA-N 1-[2,6-bis(phenylmethoxy)pyridin-3-yl]-5-bromo-3-methylbenzimidazol-2-one Chemical compound BrC1=CC2=C(N(C(N2C)=O)C=2C(=NC(=CC=2)OCC2=CC=CC=C2)OCC2=CC=CC=C2)C=C1 DFKWGHKQFSKDDL-UHFFFAOYSA-N 0.000 description 1
- MWYFDHRLYOKUMH-UHFFFAOYSA-N 1-bromo-2-fluoro-3-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC(Br)=C1F MWYFDHRLYOKUMH-UHFFFAOYSA-N 0.000 description 1
- JILHZKWLEAKYRC-UHFFFAOYSA-N 1-methoxy-2,2-dimethylpropane Chemical compound COCC(C)(C)C JILHZKWLEAKYRC-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- GPYLCFQEKPUWLD-UHFFFAOYSA-N 1h-benzo[cd]indol-2-one Chemical compound C1=CC(C(=O)N2)=C3C2=CC=CC3=C1 GPYLCFQEKPUWLD-UHFFFAOYSA-N 0.000 description 1
- OXBLVCZKDOZZOJ-UHFFFAOYSA-N 2,3-Dihydrothiophene Chemical compound C1CC=CS1 OXBLVCZKDOZZOJ-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- MJVZSRZTBDMYLX-UHFFFAOYSA-N 2,6-dichloropyridin-3-amine Chemical compound NC1=CC=C(Cl)N=C1Cl MJVZSRZTBDMYLX-UHFFFAOYSA-N 0.000 description 1
- FILKGCRCWDMBKA-UHFFFAOYSA-N 2,6-dichloropyridine Chemical compound ClC1=CC=CC(Cl)=N1 FILKGCRCWDMBKA-UHFFFAOYSA-N 0.000 description 1
- JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- QQDCXQURAAVVHQ-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl methanesulfonate Chemical compound CC(C)(C)OC(=O)NCCOS(C)(=O)=O QQDCXQURAAVVHQ-UHFFFAOYSA-N 0.000 description 1
- JXEOPBDGSJRRMT-UHFFFAOYSA-N 2-[4-[1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxobenzimidazol-4-yl]piperidin-1-yl]acetic acid Chemical compound O=C1NC(CCC1N1C(N(C2=C1C=CC=C2C1CCN(CC1)CC(=O)O)C)=O)=O JXEOPBDGSJRRMT-UHFFFAOYSA-N 0.000 description 1
- SUNKGOGGABKCGU-UHFFFAOYSA-N 2-[4-[1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxobenzimidazol-5-yl]piperidin-1-yl]-N-[2-[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxyethyl]acetamide Chemical compound O=C1NC(CCC1N1C(N(C2=C1C=CC(=C2)C1CCN(CC1)CC(=O)NCCOC1=CC2=C(C(=C(C=C2C=C1)O)N1S(NC(C1)=O)(=O)=O)F)C)=O)=O SUNKGOGGABKCGU-UHFFFAOYSA-N 0.000 description 1
- LRGLFYOYKPSPJQ-UHFFFAOYSA-N 2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]acetic acid Chemical compound O=C1C=2C(NCC(=O)O)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O LRGLFYOYKPSPJQ-UHFFFAOYSA-N 0.000 description 1
- APXBGFJKKWENNW-UHFFFAOYSA-N 2-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]amino]acetic acid Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1)NCC(=O)O)=O)=O APXBGFJKKWENNW-UHFFFAOYSA-N 0.000 description 1
- ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical compound C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 description 1
- VUGCBIWQHSRQBZ-UHFFFAOYSA-N 2-methylbut-3-yn-2-amine Chemical compound CC(C)(N)C#C VUGCBIWQHSRQBZ-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- 125000001627 3 membered heterocyclic group Chemical group 0.000 description 1
- VEEAXSFVSKDNOV-UHFFFAOYSA-N 3-[4-[1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxobenzimidazol-5-yl]piperidin-1-yl]-N-[2-[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxyethyl]propanamide Chemical compound O=C1NC(CCC1N1C(N(C2=C1C=CC(=C2)C1CCN(CC1)CCC(=O)NCCOC1=CC2=C(C(=C(C=C2C=C1)O)N1S(NC(C1)=O)(=O)=O)F)C)=O)=O VEEAXSFVSKDNOV-UHFFFAOYSA-N 0.000 description 1
- DHXNZYCXMFBMHE-UHFFFAOYSA-N 3-bromopropanoic acid Chemical compound OC(=O)CCBr DHXNZYCXMFBMHE-UHFFFAOYSA-N 0.000 description 1
- SLMKWBBOGMHYGT-UHFFFAOYSA-N 3-iodo-2,6-bis(phenylmethoxy)pyridine Chemical compound C1=CC=CC=C1COC1=NC(=CC=C1I)OCC1=CC=CC=C1 SLMKWBBOGMHYGT-UHFFFAOYSA-N 0.000 description 1
- 125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 1
- YWSITNKCZVAVCM-UHFFFAOYSA-N 3-phenylmethoxynaphthalen-2-amine Chemical compound NC1=CC2=CC=CC=C2C=C1OCC1=CC=CC=C1 YWSITNKCZVAVCM-UHFFFAOYSA-N 0.000 description 1
- 125000001963 4 membered heterocyclic group Chemical group 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- YTMVYYAKOPIJCZ-UHFFFAOYSA-N 4-bromo-3-fluoroaniline Chemical compound NC1=CC=C(Br)C(F)=C1 YTMVYYAKOPIJCZ-UHFFFAOYSA-N 0.000 description 1
- YZHISWFETIQQNM-UHFFFAOYSA-N 5-bromo-2-iodo-N-methylaniline Chemical compound CNc1cc(Br)ccc1I YZHISWFETIQQNM-UHFFFAOYSA-N 0.000 description 1
- XVMKZAAFVWXIII-UHFFFAOYSA-N 5-fluoro-2-benzofuran-1,3-dione Chemical compound FC1=CC=C2C(=O)OC(=O)C2=C1 XVMKZAAFVWXIII-UHFFFAOYSA-N 0.000 description 1
- WMKDUJVLNZANRN-UHFFFAOYSA-N 6-bromo-1h-indazole Chemical compound BrC1=CC=C2C=NNC2=C1 WMKDUJVLNZANRN-UHFFFAOYSA-N 0.000 description 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 description 1
- 125000005330 8 membered heterocyclic group Chemical group 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- 101710094481 Cullin-4 Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 1
- 102100023877 E3 ubiquitin-protein ligase RBX1 Human genes 0.000 description 1
- 101710095156 E3 ubiquitin-protein ligase RBX1 Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229940032072 GVAX vaccine Drugs 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 101001111722 Homo sapiens E3 ubiquitin-protein ligase RBX1 Proteins 0.000 description 1
- 101000574654 Homo sapiens GTP-binding protein Rit1 Proteins 0.000 description 1
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 1
- 101001001420 Homo sapiens Interferon gamma receptor 1 Proteins 0.000 description 1
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102100035678 Interferon gamma receptor 1 Human genes 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 102100031775 Leptin receptor Human genes 0.000 description 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 108010052419 NF-KappaB Inhibitor alpha Proteins 0.000 description 1
- 102100039337 NF-kappa-B inhibitor alpha Human genes 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 239000012425 OXONE® Substances 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- 108010001441 Phosphopeptides Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 101710178916 RING-box protein 1 Proteins 0.000 description 1
- 102000034442 RING-type E3 ubiquitin transferases Human genes 0.000 description 1
- 108030001238 RING-type E3 ubiquitin transferases Proteins 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 102000001712 STAT5 Transcription Factor Human genes 0.000 description 1
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 1
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 1
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000012391 XPhos Pd G2 Substances 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000002009 alkene group Chemical group 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 102000000472 beta-Transducin Repeat-Containing Proteins Human genes 0.000 description 1
- 108010080842 beta-Transducin Repeat-Containing Proteins Proteins 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 239000004305 biphenyl Chemical group 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- QHXLIQMGIGEHJP-UHFFFAOYSA-N boron;2-methylpyridine Chemical compound [B].CC1=CC=CC=N1 QHXLIQMGIGEHJP-UHFFFAOYSA-N 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 238000000451 chemical ionisation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- DDNKJFBQMQOIKI-UHFFFAOYSA-N cincreasin Chemical compound BrC1=CC=C2NC(=O)OC2=C1 DDNKJFBQMQOIKI-UHFFFAOYSA-N 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
- ZXIJMRYMVAMXQP-UHFFFAOYSA-N cycloheptene Chemical compound C1CCC=CCC1 ZXIJMRYMVAMXQP-UHFFFAOYSA-N 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 1
- 125000004090 cyclononenyl group Chemical group C1(=CCCCCCCC1)* 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 102000022604 damaged DNA binding proteins Human genes 0.000 description 1
- 108091013406 damaged DNA binding proteins Proteins 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000006009 dihaloalkoxy group Chemical group 0.000 description 1
- 125000004982 dihaloalkyl group Chemical group 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004582 dihydrobenzothienyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- WDUDHEOUGWAKFD-UHFFFAOYSA-N ditert-butyl(cyclopenta-2,4-dien-1-yl)phosphane;iron(2+) Chemical compound [Fe+2].CC(C)(C)P(C(C)(C)C)C1=CC=C[CH-]1.CC(C)(C)P(C(C)(C)C)C1=CC=C[CH-]1 WDUDHEOUGWAKFD-UHFFFAOYSA-N 0.000 description 1
- SACNIGZYDTUHKB-UHFFFAOYSA-N ditert-butyl-[2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C(C)(C)C)C(C)(C)C SACNIGZYDTUHKB-UHFFFAOYSA-N 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- OCVXZQOKBHXGRU-UHFFFAOYSA-N iodine(1+) Chemical group [I+] OCVXZQOKBHXGRU-UHFFFAOYSA-N 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 108010019813 leptin receptors Proteins 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical compound [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
- CYEXEOXALMJXDI-UHFFFAOYSA-N methyl 4-bromo-2-methylbenzoate Chemical compound COC(=O)C1=CC=C(Br)C=C1C CYEXEOXALMJXDI-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000006682 monohaloalkyl group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001298 n-hexoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 125000005882 oxadiazolinyl group Chemical group 0.000 description 1
- 125000005880 oxathiolanyl group Chemical group 0.000 description 1
- UHHKSVZZTYJVEG-UHFFFAOYSA-N oxepane Chemical compound C1CCCOCC1 UHHKSVZZTYJVEG-UHFFFAOYSA-N 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 1
- SRJOCJYGOFTFLH-UHFFFAOYSA-M piperidine-4-carboxylate Chemical compound [O-]C(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-M 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- OKBMCNHOEMXPTM-UHFFFAOYSA-M potassium peroxymonosulfate Chemical compound [K+].OOS([O-])(=O)=O OKBMCNHOEMXPTM-UHFFFAOYSA-M 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 230000004063 proteosomal degradation Effects 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000005554 pyridyloxy group Chemical group 0.000 description 1
- NPWMTBZSRRLQNJ-UHFFFAOYSA-N pyroglutamine Chemical compound NC1CCC(=O)NC1=O NPWMTBZSRRLQNJ-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000007363 regulatory process Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000028706 ribosome biogenesis Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- WPGLRFGDZJSQGI-UHFFFAOYSA-N tert-butyl 3-aminoazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(N)C1 WPGLRFGDZJSQGI-UHFFFAOYSA-N 0.000 description 1
- XRRXRQJQQKMFBC-UHFFFAOYSA-N tert-butyl 3-hydroxyazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(O)C1 XRRXRQJQQKMFBC-UHFFFAOYSA-N 0.000 description 1
- BUQNEWLXUXVZQI-UHFFFAOYSA-N tert-butyl 4-[1-[2,6-bis(phenylmethoxy)pyridin-3-yl]-3-methyl-2-oxobenzimidazol-4-yl]oxypiperidine-1-carboxylate Chemical compound C(C1=CC=CC=C1)OC1=NC(=CC=C1N1C(N(C2=C1C=CC=C2OC1CCN(CC1)C(=O)OC(C)(C)C)C)=O)OCC1=CC=CC=C1 BUQNEWLXUXVZQI-UHFFFAOYSA-N 0.000 description 1
- WOEQSXAIPTXOPY-UHFFFAOYSA-N tert-butyl 4-methylsulfonyloxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(OS(C)(=O)=O)CC1 WOEQSXAIPTXOPY-UHFFFAOYSA-N 0.000 description 1
- QUERMGFVJPRMJL-UHFFFAOYSA-N tert-butyl azetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC1 QUERMGFVJPRMJL-UHFFFAOYSA-N 0.000 description 1
- CKXZPVPIDOJLLM-UHFFFAOYSA-N tert-butyl n-piperidin-4-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCNCC1 CKXZPVPIDOJLLM-UHFFFAOYSA-N 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000005305 thiadiazolinyl group Chemical group 0.000 description 1
- 125000001583 thiepanyl group Chemical group 0.000 description 1
- VOVUARRWDCVURC-UHFFFAOYSA-N thiirane Chemical compound C1CS1 VOVUARRWDCVURC-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 125000005881 triazolinyl group Chemical group 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000004952 trihaloalkoxy group Chemical group 0.000 description 1
- 125000004385 trihaloalkyl group Chemical group 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962952161P | 2019-12-20 | 2019-12-20 | |
| US201962952097P | 2019-12-20 | 2019-12-20 | |
| US62/952,161 | 2019-12-20 | ||
| US62/952,097 | 2019-12-20 | ||
| US202063121721P | 2020-12-04 | 2020-12-04 | |
| US63/121,721 | 2020-12-04 | ||
| US202063125937P | 2020-12-15 | 2020-12-15 | |
| US63/125,937 | 2020-12-15 | ||
| PCT/US2020/066243 WO2021127586A1 (en) | 2019-12-20 | 2020-12-18 | Protein tyrosine phosphatase degraders and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116194453A true CN116194453A (zh) | 2023-05-30 |
Family
ID=74206162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080097241.6A Pending CN116194453A (zh) | 2019-12-20 | 2020-12-18 | 蛋白质酪氨酸磷酸酶降解剂及其使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240383886A1 (https=) |
| EP (1) | EP4077319A1 (https=) |
| JP (1) | JP7828893B2 (https=) |
| CN (1) | CN116194453A (https=) |
| AU (1) | AU2020407244A1 (https=) |
| CA (1) | CA3162364A1 (https=) |
| TW (1) | TWI879854B (https=) |
| UY (1) | UY38999A (https=) |
| WO (1) | WO2021127586A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117343052A (zh) * | 2023-12-04 | 2024-01-05 | 英矽智能科技(上海)有限公司 | 蛋白酪氨酸磷酸酶抑制剂及其应用 |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120172958A (zh) | 2019-04-12 | 2025-06-20 | C4医药公司 | Ikaros和aiolos的三环降解物 |
| JP2023506227A (ja) | 2019-12-12 | 2023-02-15 | カムクワット バイオサイエンシーズ インコーポレイテッド | 免疫活性を強化するための組成物および方法 |
| WO2021222542A1 (en) * | 2020-04-30 | 2021-11-04 | President And Fellows Of Harvard College | 5-amino-2-piperidinon-3-yl-1-oxoisoindoline derivatives for degradation of ikzf2 degraders |
| IL302038A (en) * | 2020-10-14 | 2023-06-01 | C4 Therapeutics Inc | Tricyclic ligands for degradation of ikzf2 or ikzf4 |
| EP4228625A4 (en) * | 2020-10-14 | 2026-01-14 | C4 Therapeutics Inc | TRICYCLIC HETEROBFUNCTIONAL COMPOUNDS FOR TARGETED PROTEIN DEGRADATION |
| CN116457339A (zh) * | 2020-10-14 | 2023-07-18 | C4医药公司 | 用于医学治疗的降解新底物的三环化合物 |
| WO2022161414A1 (zh) * | 2021-01-26 | 2022-08-04 | 成都茵创园医药科技有限公司 | 芳香化合物、含其的药物组合物及其应用 |
| KR20240017814A (ko) | 2021-05-05 | 2024-02-08 | 바이오젠 엠에이 인코포레이티드 | 브루톤 티로신 키나제의 분해를 표적으로 하는 화합물 |
| WO2022271727A1 (en) * | 2021-06-21 | 2022-12-29 | Calico Life Sciences Llc | Degrader compounds and uses thereof |
| KR20240035526A (ko) | 2021-07-07 | 2024-03-15 | 바이오젠 엠에이 인코포레이티드 | Irak4 단백질의 분해를 표적하는 화합물 |
| AU2022326553A1 (en) * | 2021-08-10 | 2024-03-28 | Abbvie Inc. | Protein tyrosine phosphatase targeting ligands |
| CN118201923A (zh) * | 2021-10-15 | 2024-06-14 | 海南先声再明医药股份有限公司 | 三环类化合物 |
| TW202333670A (zh) * | 2022-01-04 | 2023-09-01 | 大陸商海思科醫藥集團股份有限公司 | 抑制並降解irak4的化合物及其藥物组合物和藥學上的應用 |
| MA69177B1 (fr) * | 2022-06-06 | 2026-03-31 | Treeline Biosciences, Inc. | Agents de dégradation bifonctionnels de quinolone-bcl6 tricycliques |
| CN120981456A (zh) | 2023-05-24 | 2025-11-18 | 金橘生物科技公司 | 杂环化合物及其用途 |
| KR20260040037A (ko) | 2023-07-14 | 2026-03-23 | 카톨리에케 유니버시테이트 루벤 | 암 및 대사 질병의 치료를 위한 신규 화합물 |
| TW202535389A (zh) | 2023-10-18 | 2025-09-16 | 香港商北嶺健康集團(香港)有限公司 | Ｐｔｐｎ２／ｐｔｐ１ｂ降解劑及其治療方法 |
| US12565492B2 (en) | 2024-08-09 | 2026-03-03 | Triana Biomedicines, Inc. | Anaplastic Lymphoma Kinase (ALK) degraders and uses thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101326173A (zh) * | 2005-12-08 | 2008-12-17 | 诺瓦提斯公司 | 作为抗糖尿病剂的噻二唑衍生物 |
| CN101336235A (zh) * | 2005-12-08 | 2008-12-31 | 诺瓦提斯公司 | 作为ptp-酶抑制剂的1-邻氟苯基取代的1,2,5-噻唑烷二酮衍生物 |
| WO2017197046A1 (en) * | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR066820A1 (es) * | 2007-06-04 | 2009-09-16 | Novartis Ag | Compuestos de tiadiazolidin-3 ona |
| EP3535254A4 (en) | 2016-11-01 | 2020-06-24 | Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") | COMPOUNDS FOR THE DEGRADATION OF MALT1 |
| EP4717317A2 (en) | 2017-06-20 | 2026-04-01 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| MX2020003190A (es) * | 2017-09-22 | 2020-11-11 | Kymera Therapeutics Inc | Degradadores de proteinas y usos de los mismos. |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
-
2020
- 2020-12-18 US US17/787,828 patent/US20240383886A1/en active Pending
- 2020-12-18 WO PCT/US2020/066243 patent/WO2021127586A1/en not_active Ceased
- 2020-12-18 CN CN202080097241.6A patent/CN116194453A/zh active Pending
- 2020-12-18 EP EP20845470.2A patent/EP4077319A1/en active Pending
- 2020-12-18 CA CA3162364A patent/CA3162364A1/en active Pending
- 2020-12-18 AU AU2020407244A patent/AU2020407244A1/en active Pending
- 2020-12-18 JP JP2022538068A patent/JP7828893B2/ja active Active
- 2020-12-21 UY UY0001038999A patent/UY38999A/es unknown
- 2020-12-21 TW TW109145346A patent/TWI879854B/zh active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101326173A (zh) * | 2005-12-08 | 2008-12-17 | 诺瓦提斯公司 | 作为抗糖尿病剂的噻二唑衍生物 |
| CN101336235A (zh) * | 2005-12-08 | 2008-12-31 | 诺瓦提斯公司 | 作为ptp-酶抑制剂的1-邻氟苯基取代的1,2,5-噻唑烷二酮衍生物 |
| WO2017197046A1 (en) * | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117343052A (zh) * | 2023-12-04 | 2024-01-05 | 英矽智能科技(上海)有限公司 | 蛋白酪氨酸磷酸酶抑制剂及其应用 |
| CN117343052B (zh) * | 2023-12-04 | 2024-02-06 | 英矽智能科技(上海)有限公司 | 蛋白酪氨酸磷酸酶抑制剂及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| UY38999A (es) | 2021-07-30 |
| EP4077319A1 (en) | 2022-10-26 |
| WO2021127586A1 (en) | 2021-06-24 |
| JP2023508914A (ja) | 2023-03-06 |
| CA3162364A1 (en) | 2021-06-24 |
| TW202136250A (zh) | 2021-10-01 |
| TWI879854B (zh) | 2025-04-11 |
| US20240383886A1 (en) | 2024-11-21 |
| AU2020407244A1 (en) | 2022-07-28 |
| JP7828893B2 (ja) | 2026-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116194453A (zh) | 蛋白质酪氨酸磷酸酶降解剂及其使用方法 | |
| CN111989321B (zh) | Kras g12c抑制剂 | |
| CN103429585B (zh) | 作为白细胞介素-1受体相关激酶抑制剂的吲唑基三唑衍生物 | |
| CN117460737A (zh) | 杂芳环化合物、其制备方法及用途 | |
| CN103814027B (zh) | 四氢吡啶并-吡啶和四氢吡啶并-嘧啶化合物及其作为c5a受体调节剂的用途 | |
| CN103797011B (zh) | 作为c-Kit激酶抑制剂的化合物和组合物 | |
| CA2935880A1 (en) | Indazole compounds as irak4 inhibitors | |
| CN108473471A (zh) | 用作雄性激素受体拮抗剂的被取代的硫尿囊素衍生物 | |
| CN110678461B (zh) | Syk抑制剂及其使用方法 | |
| CN117813307A (zh) | 白介素-1受体相关激酶的双官能降解物及其治疗用途 | |
| WO2022271727A1 (en) | Degrader compounds and uses thereof | |
| KR20230005938A (ko) | Ccr6 수용체 조절인자로서의 아제티딘-3-일메탄올 유도체 | |
| AU2005213538A1 (en) | Piperidinylcarbonyl-pyrrolidines and their use as melanocortin agonists | |
| EP3292110B1 (en) | N-piperidin-4-yl derivatives | |
| CN111269217A (zh) | 一种嘧啶胺类化合物、其制备方法及应用 | |
| CN113149996A (zh) | 一种作为cdk9抑制剂的多环酰胺类衍生物、其制备方法及用途 | |
| JP7080900B2 (ja) | Ｐｉ３－キナーゼ活性の阻害剤としてのオキセピノピラゾール誘導体 | |
| CN120981467A (zh) | 一种egfr突变抑制剂及其应用 | |
| HK40107816A (zh) | 白介素-1受体相关激酶的双官能降解物及其治疗用途 | |
| HK1259899A1 (en) | Substituted thiohydantoin derivatives as androgen receptor antagonists | |
| HK1191938B (en) | Indazolyl triazole derivatives as irak inhibitors | |
| HK40015394A (en) | Syk inhibitor and use method therefor | |
| HK40015394B (en) | Syk inhibitor and use method therefor | |
| HK1196359B (en) | Imidazopyridazine compounds | |
| HK1200162B (en) | Substituted indazole derivatives active as kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |